[
    {
        "_id": "440234753",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440234753,
                "generic_name": "apadamtase alfa",
                "designated_date": "2020-09-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baxalta US Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Sickle Cell Disease",
                    "umls": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "404772603",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772603,
                "generic_name": "apadamtase alfa",
                "designated_date": "2020-09-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baxalta US Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Sickle Cell Disease",
                    "umls": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "381128258",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381128258,
                "generic_name": "apadamtase alfa",
                "designated_date": "2020-09-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Baxalta US Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Sickle Cell Disease",
                    "umls": "C0002895",
                    "parsed_text": "Sickle Cell Disease"
                }
            }
        ]
    },
    {
        "_id": "405023558",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 405023558,
                "generic_name": "1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer",
                "designated_date": "2018-03-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Trillium Therapeutics Inc.|2488 Dunwin Drive|Mississauga|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of Cutaneous T-Cell Lymphoma",
                    "umls": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "332853708",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 332853708,
                "generic_name": "2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",
                "designated_date": "2010-09-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GenKyoTex S.A.|14 Chemin des Aulx|Geneva|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic pulmonary fibrosis.",
                    "umls": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "319393237",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 319393237,
                "generic_name": "2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one",
                "designated_date": "2019-04-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Aprea Therapeutics AB|Nobels Vag 3|Solna,|Sweden",
                "orphan_designation": {
                    "original_text": "Treatment of Myelodysplastic Syndrome",
                    "umls": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "369038179",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 369038179,
                "generic_name": "2-hydroxypropyl-B-cyclodextrin",
                "designated_date": "2013-02-18",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vtesse, Inc.|700 Technology Square|Third Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Niemann Pick disease, type C.",
                    "umls": "C0220756",
                    "parsed_text": [
                        "Niemann Pick Disease",
                        "Type C"
                    ]
                }
            }
        ]
    },
    {
        "_id": "255374991",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 255374991,
                "generic_name": "2-hydroxypropyl-B-cyclodextrin",
                "designated_date": "2013-02-18",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vtesse, Inc.|700 Technology Square|Third Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Niemann Pick disease, type C.",
                    "umls": "C0220756",
                    "parsed_text": [
                        "Niemann Pick Disease",
                        "Type C"
                    ]
                }
            }
        ]
    },
    {
        "_id": "254764800",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 254764800,
                "generic_name": "2-hydroxypropyl-B-cyclodextrin",
                "designated_date": "2013-02-18",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Vtesse, Inc.|700 Technology Square|Third Floor|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Niemann Pick disease, type C.",
                    "umls": "C0220756",
                    "parsed_text": [
                        "Niemann Pick Disease",
                        "Type C"
                    ]
                }
            }
        ]
    },
    {
        "_id": "404772496",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772496,
                "generic_name": "225Ac-lintuzumab",
                "designated_date": "2014-11-25",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actinium Pharmaceuticals, Inc.|379 Thornall Avenue|6th Floor|Edison|New Jersey|8837|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "402426007",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 402426007,
                "generic_name": "225Ac-lintuzumab",
                "designated_date": "2014-11-25",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Actinium Pharmaceuticals, Inc.|379 Thornall Avenue|6th Floor|Edison|New Jersey|8837|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "223844000",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 223844000,
                "generic_name": "4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",
                "designated_date": "2015-09-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Recursion Pharmaceuticals, LLC|383 S. Colorow Drive|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cerebral cavernous malformation.",
                    "umls": "C2919945",
                    "parsed_text": "Cerebral Cavernous Malformation"
                }
            }
        ]
    },
    {
        "_id": "117651832",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 117651832,
                "generic_name": "4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",
                "designated_date": "2015-09-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Recursion Pharmaceuticals, LLC|383 S. Colorow Drive|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cerebral cavernous malformation.",
                    "umls": "C2919945",
                    "parsed_text": "Cerebral Cavernous Malformation"
                }
            }
        ]
    },
    {
        "_id": "53789268",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 53789268,
                "generic_name": "4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",
                "designated_date": "2015-09-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Recursion Pharmaceuticals, LLC|383 S. Colorow Drive|Salt Lake City|Utah|84108|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cerebral cavernous malformation.",
                    "umls": "C2919945",
                    "parsed_text": "Cerebral Cavernous Malformation"
                }
            }
        ]
    },
    {
        "_id": "319393478",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 319393478,
                "generic_name": "4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid",
                "designated_date": "2014-05-19",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Roche Genentech|F. Hoffmann-La Roche Ltd.|430 East 29th Street|New York|New York|10016|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Acute Myeloid Leukemia",
                    "umls": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            }
        ]
    },
    {
        "_id": "160687627",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160687627,
                "generic_name": "90Y-hPAMA4",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "404719631",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404719631,
                "generic_name": "A-dmDT390-bisFv(UCHT1)",
                "designated_date": "2014-10-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Angimmune, LLC|American Red Cross Holland Laboratory|15601 Crabbs Branch Way|Rockville|Maryland|20855|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cutaneous T-cell lymphoma",
                    "umls": "C0079773",
                    "parsed_text": "cutaneous T-cell lymphoma"
                }
            }
        ]
    },
    {
        "_id": "255366256",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 255366256,
                "generic_name": "abagovomab",
                "designated_date": "2003-11-25",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of epithelial ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Epithelial Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "252166477",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 252166477,
                "generic_name": "abagovomab",
                "designated_date": "2003-11-25",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of epithelial ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Epithelial Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "160693407",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160693407,
                "generic_name": "abagovomab",
                "designated_date": "2003-11-25",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of epithelial ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Epithelial Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "135318753",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135318753,
                "generic_name": "abagovomab",
                "designated_date": "2003-11-25",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of epithelial ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Epithelial Ovarian Cancer"
                }
            }
        ]
    },
    {
        "_id": "441072535",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 441072535,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 441072535,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 441072535,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 441072535,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "440790639",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790639,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 440790639,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 440790639,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 440790639,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "386474197",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 386474197,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 386474197,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 386474197,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 386474197,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "386467149",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 386467149,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 386467149,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 386467149,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 386467149,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "178103473",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103473,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 178103473,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 178103473,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 178103473,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "135355129",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135355129,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 135355129,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 135355129,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 135355129,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "103771521",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771521,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 103771521,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 103771521,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 103771521,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "50070209",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50070209,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 50070209,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 50070209,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 50070209,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "46509198",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46509198,
                "generic_name": "abatacept",
                "designated_date": "2013-05-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States",
                "orphan_designation": {
                    "original_text": "Treatment of type 1 diabetes mellitus patients with residual beta cell function",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 46509198,
                "generic_name": "abatacept",
                "designated_date": "2017-12-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prevention of Graft versus Host Disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 46509198,
                "generic_name": "Abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of giant cell arteritis",
                    "umls": "C0039483",
                    "parsed_text": "Giant Cell Arteritis"
                }
            },
            {
                "pubchem_sid": 46509198,
                "generic_name": "abatacept",
                "designated_date": "2017-02-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Treatment of idiopathic inflammatory myopathy (IIM)",
                    "umls": [
                        "C0751356",
                        "C3888318"
                    ],
                    "parsed_text": [
                        "idiopathic inflammatory myopathy",
                        "IIM"
                    ]
                }
            }
        ]
    },
    {
        "_id": "404770371",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404770371,
                "generic_name": "Abetimus",
                "designated_date": "2000-07-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Co.|6455 Nancy Ridge Dr.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lupus nephritis.",
                    "umls": "C0024143",
                    "parsed_text": "Lupus Nephritis"
                }
            }
        ]
    },
    {
        "_id": "160687556",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160687556,
                "generic_name": "Abetimus",
                "designated_date": "2000-07-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Co.|6455 Nancy Ridge Dr.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lupus nephritis.",
                    "umls": "C0024143",
                    "parsed_text": "Lupus Nephritis"
                }
            }
        ]
    },
    {
        "_id": "135325229",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135325229,
                "generic_name": "Abetimus",
                "designated_date": "2000-07-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "La Jolla Pharmaceutical Co.|6455 Nancy Ridge Dr.|San Diego|California|92121|United States",
                "orphan_designation": {
                    "original_text": "Treatment of lupus nephritis.",
                    "umls": "C0024143",
                    "parsed_text": "Lupus Nephritis"
                }
            }
        ]
    },
    {
        "_id": "441072525",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 441072525,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "440790468",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 440790468,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "387061214",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 387061214,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "385327551",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 385327551,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "384647094",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 384647094,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "354355035",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 354355035,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "329976965",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 329976965,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "178101561",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 178101561,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "135335742",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 135335742,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "103771314",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 103771314,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "50070208",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 50070208,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "46504982",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.",
                "marketing_approval_date": "2014-09-30",
                "exclusivity_end_date": "2021-09-30",
                "exclusivity_protected_indication": "Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2011-05-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older",
                "marketing_approval_date": "2021-02-24",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric patients with ulcerative colitis",
                    "umls": "C0009324",
                    "parsed_text": "Ulcerative Colitis"
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "marketing_approval_date": "2015-09-09",
                "exclusivity_end_date": "2022-09-09",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2006-10-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "marketing_approval_date": "2014-09-23",
                "exclusivity_end_date": "2021-09-23",
                "exclusivity_protected_indication": "Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",
                "sponsor": "AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric Crohn's disease",
                    "umls": "C2931133",
                    "parsed_text": "Pediatric Crohn's disease"
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "marketing_approval_date": "2016-06-30",
                "exclusivity_end_date": "2023-06-30",
                "exclusivity_protected_indication": "Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2005-03-21",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.",
                "marketing_approval_date": "2008-02-21",
                "exclusivity_end_date": "2015-02-21",
                "sponsor": "AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of juvenile rheumatoid arthritis",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "Humira",
                "designated_date": "2014-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",
                "marketing_approval_date": "2018-09-28",
                "exclusivity_end_date": "2025-09-28",
                "exclusivity_protected_indication": "Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0009450",
                        "C0030343",
                        "C0339317",
                        "C0751438"
                    ],
                    "parsed_text": [
                        "Infectious",
                        "Panuveitis",
                        "Non-infectious anterior uveitis",
                        "Posterior"
                    ]
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "designated_date": "2014-07-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Mucora|32b Eisenberg St|Rehovot 7628810|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 46504982,
                "generic_name": "adalimumab",
                "trade_name": "HUMIRA",
                "designated_date": "2015-05-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.",
                "marketing_approval_date": "2018-10-16",
                "exclusivity_end_date": "2025-10-16",
                "exclusivity_protected_indication": "Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.",
                "sponsor": "AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)",
                    "umls": "C0162836",
                    "parsed_text": "Hidradenitis Suppurativa"
                }
            }
        ]
    },
    {
        "_id": "441071826",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 441071826,
                "generic_name": "aflibercept",
                "designated_date": "2019-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Retinopathy of Prematurity",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "354355041",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 354355041,
                "generic_name": "aflibercept",
                "designated_date": "2019-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Retinopathy of Prematurity",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "349353151",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349353151,
                "generic_name": "aflibercept",
                "designated_date": "2019-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Retinopathy of Prematurity",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "347910379",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910379,
                "generic_name": "aflibercept",
                "designated_date": "2019-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Retinopathy of Prematurity",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "178103392",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103392,
                "generic_name": "aflibercept",
                "designated_date": "2019-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Retinopathy of Prematurity",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "135347926",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135347926,
                "generic_name": "aflibercept",
                "designated_date": "2019-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Retinopathy of Prematurity",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "134445687",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 134445687,
                "generic_name": "aflibercept",
                "designated_date": "2019-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Retinopathy of Prematurity",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            }
        ]
    },
    {
        "_id": "440790670",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790670,
                "generic_name": "agalsidase beta",
                "trade_name": "Fabrazyme",
                "designated_date": "1988-01-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease",
                "marketing_approval_date": "2021-03-11",
                "exclusivity_end_date": "2028-03-11",
                "exclusivity_protected_indication": "treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease",
                "sponsor": "Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry's disease.",
                    "umls": "C0002986",
                    "parsed_text": "Fabry's Disease"
                }
            }
        ]
    },
    {
        "_id": "160682349",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160682349,
                "generic_name": "agalsidase beta",
                "trade_name": "Fabrazyme",
                "designated_date": "1988-01-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease",
                "marketing_approval_date": "2021-03-11",
                "exclusivity_end_date": "2028-03-11",
                "exclusivity_protected_indication": "treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease",
                "sponsor": "Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry's disease.",
                    "umls": "C0002986",
                    "parsed_text": "Fabry's Disease"
                }
            }
        ]
    },
    {
        "_id": "135311478",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135311478,
                "generic_name": "agalsidase beta",
                "trade_name": "Fabrazyme",
                "designated_date": "1988-01-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease",
                "marketing_approval_date": "2021-03-11",
                "exclusivity_end_date": "2028-03-11",
                "exclusivity_protected_indication": "treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease",
                "sponsor": "Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry's disease.",
                    "umls": "C0002986",
                    "parsed_text": "Fabry's Disease"
                }
            },
            {
                "pubchem_sid": 135311478,
                "generic_name": "Alpha-galactosidase A",
                "designated_date": "1990-07-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Desnick, Robert J. M.D.|The Mount Sinai School Of Medicine|Fifth Avenue at 100th Street, Box 1203|New York|New York|10029|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry's disease.",
                    "umls": "C0002986",
                    "parsed_text": "Fabry's Disease"
                }
            },
            {
                "pubchem_sid": 135311478,
                "generic_name": "Alpha-galactosidase A",
                "designated_date": "1998-06-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Long-term enzyme replacement therapy for the treatment of Fabry disease",
                    "umls": "C0002986",
                    "parsed_text": "Fabry Disease"
                }
            },
            {
                "pubchem_sid": 135311478,
                "generic_name": "Alpha-galactosidase A",
                "designated_date": "1991-06-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "David Calhoun, Ph.D.|Department of Chemistry|Convent Avenue & 138th Street|New York|New York|10031|United States",
                "orphan_designation": {
                    "original_text": "Treatment of alpha-galactosidase A deficiency (Fabry's disease).",
                    "umls": "C0002986",
                    "parsed_text": "alpha-Galactosidase A Deficiency"
                }
            }
        ]
    },
    {
        "_id": "46508538",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46508538,
                "generic_name": "agalsidase beta",
                "trade_name": "Fabrazyme",
                "designated_date": "1988-01-19",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease",
                "marketing_approval_date": "2021-03-11",
                "exclusivity_end_date": "2028-03-11",
                "exclusivity_protected_indication": "treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease",
                "sponsor": "Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry's disease.",
                    "umls": "C0002986",
                    "parsed_text": "Fabry's Disease"
                }
            },
            {
                "pubchem_sid": 46508538,
                "generic_name": "Alpha-galactosidase A",
                "designated_date": "1990-07-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Desnick, Robert J. M.D.|The Mount Sinai School Of Medicine|Fifth Avenue at 100th Street, Box 1203|New York|New York|10029|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Fabry's disease.",
                    "umls": "C0002986",
                    "parsed_text": "Fabry's Disease"
                }
            },
            {
                "pubchem_sid": 46508538,
                "generic_name": "Alpha-galactosidase A",
                "designated_date": "1998-06-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States",
                "orphan_designation": {
                    "original_text": "Long-term enzyme replacement therapy for the treatment of Fabry disease",
                    "umls": "C0002986",
                    "parsed_text": "Fabry Disease"
                }
            },
            {
                "pubchem_sid": 46508538,
                "generic_name": "Alpha-galactosidase A",
                "designated_date": "1991-06-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "David Calhoun, Ph.D.|Department of Chemistry|Convent Avenue & 138th Street|New York|New York|10031|United States",
                "orphan_designation": {
                    "original_text": "Treatment of alpha-galactosidase A deficiency (Fabry's disease).",
                    "umls": "C0002986",
                    "parsed_text": "alpha-Galactosidase A Deficiency"
                }
            }
        ]
    },
    {
        "_id": "404772796",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772796,
                "generic_name": "aganirsen",
                "designated_date": "2016-11-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gene Signal International SA|Route Cantonale|Lausanne|Vaud|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection.",
                    "umls": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            }
        ]
    },
    {
        "_id": "381126369",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381126369,
                "generic_name": "aganirsen",
                "designated_date": "2016-11-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gene Signal International SA|Route Cantonale|Lausanne|Vaud|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection.",
                    "umls": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            }
        ]
    },
    {
        "_id": "160693050",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160693050,
                "generic_name": "aganirsen",
                "designated_date": "2016-11-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Gene Signal International SA|Route Cantonale|Lausanne|Vaud|Switzerland",
                "orphan_designation": {
                    "original_text": "Prevention of corneal graft rejection.",
                    "umls": "C0339303",
                    "parsed_text": "Corneal graft rejection"
                }
            }
        ]
    },
    {
        "_id": "440790979",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790979,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 440790979,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 440790979,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 440790979,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 440790979,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 440790979,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "178101682",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178101682,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-05-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.",
                    "umls": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-02-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-02-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic malignant melanoma.",
                    "umls": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            },
            {
                "pubchem_sid": 178101682,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-05-03",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            }
        ]
    },
    {
        "_id": "135273161",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135273161,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-05-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.",
                    "umls": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-02-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-02-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic malignant melanoma.",
                    "umls": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            },
            {
                "pubchem_sid": 135273161,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-05-03",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            }
        ]
    },
    {
        "_id": "134224532",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 134224532,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 134224532,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 134224532,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 134224532,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 134224532,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 134224532,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "103771288",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771288,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 103771288,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 103771288,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 103771288,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 103771288,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 103771288,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "49985142",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 49985142,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 49985142,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 49985142,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 49985142,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 49985142,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 49985142,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "46508054",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46508054,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 46508054,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 46508054,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 46508054,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 46508054,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 46508054,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "597554",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 597554,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 597554,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 597554,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 597554,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 597554,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 597554,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "10105",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 10105,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1988-09-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults (>18 years old) with metastatic renal cell carcinoma.",
                "marketing_approval_date": "1992-05-05",
                "exclusivity_end_date": "1999-05-05",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Aldesleukin",
                "designated_date": "1989-03-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary immunodeficiency disease associated with T-cell defects.",
                    "umls": "C0398686",
                    "parsed_text": "Primary Immunodeficiency Disease"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Aldesleukin",
                "trade_name": "Proleukin",
                "designated_date": "1996-09-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adults with metastatic melanoma.",
                "marketing_approval_date": "1998-01-09",
                "exclusivity_end_date": "2005-01-09",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic melanoma.",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-11-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "For the treatment non-Hodgkin's lymphoma.",
                    "umls": "C0024305",
                    "parsed_text": "Non-Hodgkin's Lymphoma"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Aldesleukin",
                "designated_date": "1998-07-31",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Aldesleukin",
                "designated_date": "2020-04-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Amyotrophic Lateral Sclerosis",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-05-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.",
                    "umls": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-02-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-02-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "Treatment of metastatic malignant melanoma.",
                    "umls": "C0860594",
                    "parsed_text": "Metastatic malignant melanoma"
                }
            },
            {
                "pubchem_sid": 10105,
                "generic_name": "Interleukin-2",
                "designated_date": "1990-05-03",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States",
                "orphan_designation": {
                    "original_text": "In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.",
                    "umls": "C0278678",
                    "parsed_text": "metastatic renal cell carcinoma"
                }
            }
        ]
    },
    {
        "_id": "440790671",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790671,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "329976974",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 329976974,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "178103376",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103376,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "135330159",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135330159,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "103771414",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771414,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "50070197",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50070197,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "46507379",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46507379,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "7978474",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 7978474,
                "generic_name": "alemtuzumab",
                "trade_name": "Campath",
                "designated_date": "1997-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.",
                "marketing_approval_date": "2001-05-07",
                "exclusivity_end_date": "2008-05-07",
                "sponsor": "Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia.",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "160693092",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160693092,
                "generic_name": "algenpantucel-L",
                "designated_date": "2010-10-21",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "NewLink Genetics Corporation|2503 S. Loop Drive|Ames|Iowa|50010|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer.",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            }
        ]
    },
    {
        "_id": "438448225",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 438448225,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "381126738",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381126738,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "375563015",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 375563015,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "354355043",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 354355043,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "348653637",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 348653637,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "347910431",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910431,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "178103355",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103355,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "160709254",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160709254,
                "generic_name": "alirocumab",
                "trade_name": "Praluent",
                "designated_date": "2017-06-15",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.",
                "marketing_approval_date": "2021-04-01",
                "sponsor": "Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of homozygous familial hypercholesterolemia",
                    "umls": "C0020445",
                    "parsed_text": "FAMILIAL HYPERCHOLESTEROLEMIA"
                }
            }
        ]
    },
    {
        "_id": "349986622",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349986622,
                "generic_name": "alpha melanotropin",
                "designated_date": "2010-09-02",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "mondoBIOTECH Laboratories AG|Herrengasse 21|Furstentum Liechtenstein|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of chronic beryllium disease",
                    "umls": "C0221052",
                    "parsed_text": "Chronic beryllium disease"
                }
            }
        ]
    },
    {
        "_id": "53790846",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 53790846,
                "generic_name": "alpha melanotropin",
                "designated_date": "2010-09-02",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "mondoBIOTECH Laboratories AG|Herrengasse 21|Furstentum Liechtenstein|Germany",
                "orphan_designation": {
                    "original_text": "Treatment of chronic beryllium disease",
                    "umls": "C0221052",
                    "parsed_text": "Chronic beryllium disease"
                }
            }
        ]
    },
    {
        "_id": "404719581",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404719581,
                "generic_name": "alpha-1 proteinase inhibitor (human)",
                "designated_date": "2017-07-31",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kamada, Ltd.|2 Holtzman Street|Rehovot|Israel",
                "orphan_designation": {
                    "original_text": "Prevention of graft versus host disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 404719581,
                "generic_name": "alpha-1 proteinase inhibitor (human)",
                "designated_date": "2014-10-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kamada Ltd.|2 Holtsman Street|Rehovot|Center District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of graft versus host disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 404719581,
                "generic_name": "Alpha1-proteinase inhibitor (human)",
                "trade_name": "Prolastin",
                "designated_date": "1984-12-07",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.",
                "marketing_approval_date": "1987-12-02",
                "exclusivity_end_date": "1994-12-02",
                "sponsor": "Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.",
                    "umls": [
                        "C0162429",
                        "C0333006"
                    ],
                    "parsed_text": [
                        "Deficiency state",
                        "congenital deficiency"
                    ]
                }
            },
            {
                "pubchem_sid": 404719581,
                "generic_name": "alpha1-proteinase inhibitor (human)",
                "designated_date": "2015-03-03",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Grifols Therapeutics, Inc.|8368 US Business Hwy 70 West|Clayton|North Carolina|27520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 404719581,
                "generic_name": "alpha1-proteinase inhibitor (human)",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Grifols Therapeutics, Inc.|8368 US 70 BUS Hwy W.|Clayton|North Carolina|27520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "pubchem_sid": 404719581,
                "generic_name": "Alpha1-proteinase inhibitor (human)",
                "designated_date": "1999-11-24",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CSL Behring L.L.C.|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.",
                    "umls": [
                        "C0034067",
                        "C0242656"
                    ],
                    "parsed_text": [
                        "Emphysema",
                        "Progression"
                    ]
                }
            },
            {
                "pubchem_sid": 404719581,
                "generic_name": "alpha1-proteinase inhibitor (human)",
                "designated_date": "2009-02-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CSL Behring LLC|1020 First Avenue|P. O. Box 61501|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "pubchem_sid": 404719581,
                "generic_name": "Alpha1-Proteinase Inhibitor (Human)",
                "designated_date": "2004-09-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kamada Ltd.|7 Sapir Street|Ness Ziona|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "46506364",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46506364,
                "generic_name": "alpha-1 proteinase inhibitor (human)",
                "designated_date": "2017-07-31",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kamada, Ltd.|2 Holtzman Street|Rehovot|Israel",
                "orphan_designation": {
                    "original_text": "Prevention of graft versus host disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 46506364,
                "generic_name": "alpha-1 proteinase inhibitor (human)",
                "designated_date": "2014-10-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kamada Ltd.|2 Holtsman Street|Rehovot|Center District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of graft versus host disease",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 46506364,
                "generic_name": "Alpha1-proteinase inhibitor (human)",
                "trade_name": "Prolastin",
                "designated_date": "1984-12-07",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.",
                "marketing_approval_date": "1987-12-02",
                "exclusivity_end_date": "1994-12-02",
                "sponsor": "Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.",
                    "umls": [
                        "C0162429",
                        "C0333006"
                    ],
                    "parsed_text": [
                        "Deficiency state",
                        "congenital deficiency"
                    ]
                }
            },
            {
                "pubchem_sid": 46506364,
                "generic_name": "alpha1-proteinase inhibitor (human)",
                "designated_date": "2015-03-03",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Grifols Therapeutics, Inc.|8368 US Business Hwy 70 West|Clayton|North Carolina|27520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.",
                    "umls": "C0011854",
                    "parsed_text": "Type 1 diabetes mellitus"
                }
            },
            {
                "pubchem_sid": 46506364,
                "generic_name": "alpha1-proteinase inhibitor (human)",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Grifols Therapeutics, Inc.|8368 US 70 BUS Hwy W.|Clayton|North Carolina|27520|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "pubchem_sid": 46506364,
                "generic_name": "Alpha1-proteinase inhibitor (human)",
                "designated_date": "1999-11-24",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CSL Behring L.L.C.|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.",
                    "umls": [
                        "C0034067",
                        "C0242656"
                    ],
                    "parsed_text": [
                        "Emphysema",
                        "Progression"
                    ]
                }
            },
            {
                "pubchem_sid": 46506364,
                "generic_name": "alpha1-proteinase inhibitor (human)",
                "designated_date": "2009-02-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CSL Behring LLC|1020 First Avenue|P. O. Box 61501|King of Prussia|Pennsylvania|19406|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            },
            {
                "pubchem_sid": 46506364,
                "generic_name": "Alpha1-Proteinase Inhibitor (Human)",
                "designated_date": "2004-09-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kamada Ltd.|7 Sapir Street|Ness Ziona|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of cystic fibrosis",
                    "umls": "C0010674",
                    "parsed_text": "Cystic Fibrosis"
                }
            }
        ]
    },
    {
        "_id": "440790675",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790675,
                "generic_name": "alteplase",
                "designated_date": "2014-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of plastic bronchitis",
                    "umls": "C0264342",
                    "parsed_text": "Plastic bronchitis"
                }
            },
            {
                "pubchem_sid": 440790675,
                "generic_name": "alteplase",
                "designated_date": "2003-01-27",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage",
                    "umls": [
                        "C0240059",
                        "C2937358"
                    ],
                    "parsed_text": [
                        "Intraventricular hemorrhage",
                        "Intracerebral Hemorrhage"
                    ]
                }
            }
        ]
    },
    {
        "_id": "135358863",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135358863,
                "generic_name": "alteplase",
                "designated_date": "2014-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of plastic bronchitis",
                    "umls": "C0264342",
                    "parsed_text": "Plastic bronchitis"
                }
            },
            {
                "pubchem_sid": 135358863,
                "generic_name": "alteplase",
                "designated_date": "2003-01-27",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage",
                    "umls": [
                        "C0240059",
                        "C2937358"
                    ],
                    "parsed_text": [
                        "Intraventricular hemorrhage",
                        "Intracerebral Hemorrhage"
                    ]
                }
            }
        ]
    },
    {
        "_id": "134222947",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 134222947,
                "generic_name": "alteplase",
                "designated_date": "2014-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of plastic bronchitis",
                    "umls": "C0264342",
                    "parsed_text": "Plastic bronchitis"
                }
            },
            {
                "pubchem_sid": 134222947,
                "generic_name": "alteplase",
                "designated_date": "2003-01-27",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage",
                    "umls": [
                        "C0240059",
                        "C2937358"
                    ],
                    "parsed_text": [
                        "Intraventricular hemorrhage",
                        "Intracerebral Hemorrhage"
                    ]
                }
            },
            {
                "pubchem_sid": 134222947,
                "generic_name": "Tissue Plasminogen activator",
                "designated_date": "2011-04-18",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Catherine Amlie-Lefond, MD|University of Washington|4800 Sand Point Way NE - M/S B5552|Seattle|Washington|98105|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.",
                    "umls": [
                        "C0039585",
                        "C0948008"
                    ],
                    "parsed_text": [
                        "AIS",
                        "Ischemic stroke"
                    ]
                }
            }
        ]
    },
    {
        "_id": "103771263",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771263,
                "generic_name": "alteplase",
                "designated_date": "2014-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of plastic bronchitis",
                    "umls": "C0264342",
                    "parsed_text": "Plastic bronchitis"
                }
            },
            {
                "pubchem_sid": 103771263,
                "generic_name": "alteplase",
                "designated_date": "2003-01-27",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage",
                    "umls": [
                        "C0240059",
                        "C2937358"
                    ],
                    "parsed_text": [
                        "Intraventricular hemorrhage",
                        "Intracerebral Hemorrhage"
                    ]
                }
            }
        ]
    },
    {
        "_id": "50018415",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50018415,
                "generic_name": "alteplase",
                "designated_date": "2014-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of plastic bronchitis",
                    "umls": "C0264342",
                    "parsed_text": "Plastic bronchitis"
                }
            },
            {
                "pubchem_sid": 50018415,
                "generic_name": "alteplase",
                "designated_date": "2003-01-27",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage",
                    "umls": [
                        "C0240059",
                        "C2937358"
                    ],
                    "parsed_text": [
                        "Intraventricular hemorrhage",
                        "Intracerebral Hemorrhage"
                    ]
                }
            }
        ]
    },
    {
        "_id": "46507035",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46507035,
                "generic_name": "alteplase",
                "designated_date": "2014-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of plastic bronchitis",
                    "umls": "C0264342",
                    "parsed_text": "Plastic bronchitis"
                }
            },
            {
                "pubchem_sid": 46507035,
                "generic_name": "alteplase",
                "designated_date": "2003-01-27",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage",
                    "umls": [
                        "C0240059",
                        "C2937358"
                    ],
                    "parsed_text": [
                        "Intraventricular hemorrhage",
                        "Intracerebral Hemorrhage"
                    ]
                }
            },
            {
                "pubchem_sid": 46507035,
                "generic_name": "Tissue Plasminogen activator",
                "designated_date": "2011-04-18",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Catherine Amlie-Lefond, MD|University of Washington|4800 Sand Point Way NE - M/S B5552|Seattle|Washington|98105|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.",
                    "umls": [
                        "C0039585",
                        "C0948008"
                    ],
                    "parsed_text": [
                        "AIS",
                        "Ischemic stroke"
                    ]
                }
            }
        ]
    },
    {
        "_id": "7978677",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 7978677,
                "generic_name": "alteplase",
                "designated_date": "2014-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States",
                "orphan_designation": {
                    "original_text": "Treatment of plastic bronchitis",
                    "umls": "C0264342",
                    "parsed_text": "Plastic bronchitis"
                }
            },
            {
                "pubchem_sid": 7978677,
                "generic_name": "alteplase",
                "designated_date": "2003-01-27",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States",
                "orphan_designation": {
                    "original_text": "Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage",
                    "umls": [
                        "C0240059",
                        "C2937358"
                    ],
                    "parsed_text": [
                        "Intraventricular hemorrhage",
                        "Intracerebral Hemorrhage"
                    ]
                }
            }
        ]
    },
    {
        "_id": "347911395",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911395,
                "generic_name": "amatuximab",
                "designated_date": "2012-09-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "223366083",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 223366083,
                "generic_name": "amatuximab",
                "designated_date": "2012-09-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "160704149",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160704149,
                "generic_name": "amatuximab",
                "designated_date": "2012-09-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "135289484",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135289484,
                "generic_name": "amatuximab",
                "designated_date": "2012-09-28",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "349940505",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349940505,
                "generic_name": "Ancrod",
                "designated_date": "1989-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States",
                "orphan_designation": {
                    "original_text": "To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.",
                    "umls": "C2919015",
                    "parsed_text": "ANTICOAGULATION"
                }
            }
        ]
    },
    {
        "_id": "347909946",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347909946,
                "generic_name": "Ancrod",
                "designated_date": "1989-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States",
                "orphan_designation": {
                    "original_text": "To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.",
                    "umls": "C2919015",
                    "parsed_text": "ANTICOAGULATION"
                }
            }
        ]
    },
    {
        "_id": "160698415",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160698415,
                "generic_name": "Ancrod",
                "designated_date": "1989-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States",
                "orphan_designation": {
                    "original_text": "To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.",
                    "umls": "C2919015",
                    "parsed_text": "ANTICOAGULATION"
                }
            }
        ]
    },
    {
        "_id": "135349930",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135349930,
                "generic_name": "Ancrod",
                "designated_date": "1989-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States",
                "orphan_designation": {
                    "original_text": "To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.",
                    "umls": "C2919015",
                    "parsed_text": "ANTICOAGULATION"
                }
            }
        ]
    },
    {
        "_id": "134222369",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 134222369,
                "generic_name": "Ancrod",
                "designated_date": "1989-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States",
                "orphan_designation": {
                    "original_text": "To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.",
                    "umls": "C2919015",
                    "parsed_text": "ANTICOAGULATION"
                }
            }
        ]
    },
    {
        "_id": "50026835",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50026835,
                "generic_name": "Ancrod",
                "designated_date": "1989-10-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States",
                "orphan_designation": {
                    "original_text": "To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.",
                    "umls": "C2919015",
                    "parsed_text": "ANTICOAGULATION"
                }
            }
        ]
    },
    {
        "_id": "404772536",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772536,
                "generic_name": "anfibatide",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lee's Pharmaceutical (Hong Kong) Limited|Unit 110-11, Bio-Informatics Centre|Hong Kong Science Park|Shatin, Hong Kong|China",
                "orphan_designation": {
                    "original_text": "Treatment of thrombotic thrombocytopenic purpura.",
                    "umls": "C0857305",
                    "parsed_text": "Thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "404719663",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404719663,
                "generic_name": "anfibatide",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lee's Pharmaceutical (Hong Kong) Limited|Unit 110-11, Bio-Informatics Centre|Hong Kong Science Park|Shatin, Hong Kong|China",
                "orphan_designation": {
                    "original_text": "Treatment of thrombotic thrombocytopenic purpura.",
                    "umls": "C0857305",
                    "parsed_text": "Thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "381127770",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381127770,
                "generic_name": "anfibatide",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Lee's Pharmaceutical (Hong Kong) Limited|Unit 110-11, Bio-Informatics Centre|Hong Kong Science Park|Shatin, Hong Kong|China",
                "orphan_designation": {
                    "original_text": "Treatment of thrombotic thrombocytopenic purpura.",
                    "umls": "C0857305",
                    "parsed_text": "Thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "440234910",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440234910,
                "generic_name": "ansuvimab",
                "designated_date": "2020-03-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ridgeback Biotherapeutics LP|3162 Commodore Plaza|Suite 3E|Miami|Florida|33133-|United States",
                "orphan_designation": {
                    "original_text": "Post-exposure prophylaxis against Ebola virus infection",
                    "umls": "C0282687",
                    "parsed_text": "Ebola Virus Infection"
                }
            }
        ]
    },
    {
        "_id": "433770931",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 433770931,
                "generic_name": "ansuvimab",
                "designated_date": "2020-03-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ridgeback Biotherapeutics LP|3162 Commodore Plaza|Suite 3E|Miami|Florida|33133-|United States",
                "orphan_designation": {
                    "original_text": "Post-exposure prophylaxis against Ebola virus infection",
                    "umls": "C0282687",
                    "parsed_text": "Ebola Virus Infection"
                }
            },
            {
                "pubchem_sid": 433770931,
                "generic_name": "ansuvimab-zykl",
                "trade_name": "EBANGA",
                "designated_date": "2019-05-08",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",
                "marketing_approval_date": "2020-12-21",
                "exclusivity_end_date": "2027-12-21",
                "exclusivity_protected_indication": "treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",
                "sponsor": "Ridgeback Biotherapeutics, LP|3480 Main Highway|Unit 402|Miami|Florida|33133|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Ebola Virus Disease",
                    "umls": "C0282687",
                    "parsed_text": "Ebola Virus Disease"
                }
            }
        ]
    },
    {
        "_id": "347910401",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910401,
                "generic_name": "anthrax immune globulin (human)",
                "designated_date": "2008-07-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs",
                "marketing_approval_date": "2015-03-24",
                "exclusivity_end_date": "2022-03-24",
                "exclusivity_protected_indication": "Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs",
                "sponsor": "Cangene Corp. - Emergent Biosolutions|155 Innovation Drive|R3T 5Y3|Winnipeg, MB|Canada",
                "orphan_designation": {
                    "original_text": "Treatment of inhalational anthrax",
                    "umls": "C0155866",
                    "parsed_text": "Inhalational anthrax"
                }
            }
        ]
    },
    {
        "_id": "381125967",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381125967,
                "generic_name": "Anthrax Vaccine Adsorbed",
                "trade_name": "BioThrax",
                "designated_date": "2014-04-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",
                "marketing_approval_date": "2015-11-23",
                "exclusivity_end_date": "2022-11-23",
                "exclusivity_protected_indication": "For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",
                "sponsor": "Emergent BioDefense Operations Lansing LLC|300 Proessional Drive|Gaithersburg|Maryland|20879|United States",
                "orphan_designation": {
                    "original_text": "For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure",
                    "umls": "C0003175",
                    "parsed_text": "Anthrax disease"
                }
            }
        ]
    },
    {
        "_id": "347911075",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911075,
                "generic_name": "Anthrax Vaccine Adsorbed",
                "trade_name": "BioThrax",
                "designated_date": "2014-04-11",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",
                "marketing_approval_date": "2015-11-23",
                "exclusivity_end_date": "2022-11-23",
                "exclusivity_protected_indication": "For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",
                "sponsor": "Emergent BioDefense Operations Lansing LLC|300 Proessional Drive|Gaithersburg|Maryland|20879|United States",
                "orphan_designation": {
                    "original_text": "For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure",
                    "umls": "C0003175",
                    "parsed_text": "Anthrax disease"
                }
            }
        ]
    },
    {
        "_id": "381127989",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381127989,
                "generic_name": "Anti-eTau Humanized IgG4 Monoclonal Antibody",
                "designated_date": "2015-05-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Biogen, Inc.|225 Binney Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Progressive Supranuclear Palsy",
                    "umls": "C0038868",
                    "parsed_text": "Progressive supranuclear palsy"
                }
            }
        ]
    },
    {
        "_id": "404719773",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404719773,
                "generic_name": "anti-inhibitor coagulant complex",
                "trade_name": "FEIBA",
                "designated_date": "2013-04-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                "marketing_approval_date": "2013-12-16",
                "exclusivity_end_date": "2020-12-16",
                "exclusivity_protected_indication": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                "sponsor": "Baxalta US, Inc.|One Baxter Way|West Lake Village|California|91362|United States",
                "orphan_designation": {
                    "original_text": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                    "umls": "C0019069",
                    "parsed_text": "Hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "347911435",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911435,
                "generic_name": "anti-inhibitor coagulant complex",
                "trade_name": "FEIBA",
                "designated_date": "2013-04-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                "marketing_approval_date": "2013-12-16",
                "exclusivity_end_date": "2020-12-16",
                "exclusivity_protected_indication": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                "sponsor": "Baxalta US, Inc.|One Baxter Way|West Lake Village|California|91362|United States",
                "orphan_designation": {
                    "original_text": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                    "umls": "C0019069",
                    "parsed_text": "Hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "135300895",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135300895,
                "generic_name": "anti-inhibitor coagulant complex",
                "trade_name": "FEIBA",
                "designated_date": "2013-04-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                "marketing_approval_date": "2013-12-16",
                "exclusivity_end_date": "2020-12-16",
                "exclusivity_protected_indication": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                "sponsor": "Baxalta US, Inc.|One Baxter Way|West Lake Village|California|91362|United States",
                "orphan_designation": {
                    "original_text": "Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors",
                    "umls": "C0019069",
                    "parsed_text": "Hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "46506920",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46506920,
                "generic_name": "anti-T-lymphocyte immune globulin, rabbit",
                "designated_date": "2010-03-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neovii Biotech NA, Inc.|6 Liberty Square|PMB #295|Boston|Massachusetts|2109|United States",
                "orphan_designation": {
                    "original_text": "Prevention of graft versus host disease (GVHD)",
                    "umls": "C0018133",
                    "parsed_text": "GRAFT VERSUS HOST DISEASE"
                }
            },
            {
                "pubchem_sid": 46506920,
                "generic_name": "anti-T-lymphocyte immune globulin, rabbit",
                "designated_date": "2008-09-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Neovii Biotech NA, Inc.|6 Liberty Square|PMB #295|Boston|Massachusetts|2109|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation",
                    "umls": "C1735634",
                    "parsed_text": "Acute allograft rejection"
                }
            },
            {
                "pubchem_sid": 46506920,
                "generic_name": "anti-thymocyte Globulin (rabbit)",
                "designated_date": "2000-09-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corporation|A Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "134223943",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 134223943,
                "generic_name": "anti-thymocyte Globulin (rabbit)",
                "designated_date": "2000-09-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme Corporation|A Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            }
        ]
    },
    {
        "_id": "135293379",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135293379,
                "generic_name": "Antihemophilic factor (recombinant)",
                "trade_name": "ReFacto, Xyntha",
                "designated_date": "1996-02-08",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "2000-03-06",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).",
                    "umls": [
                        "C0019069",
                        "C2674164"
                    ],
                    "parsed_text": [
                        "Hemophilia A",
                        "Hemorrhagic episodes"
                    ]
                }
            },
            {
                "pubchem_sid": 135293379,
                "generic_name": "Antihemophilic factor (recombinant)",
                "trade_name": "Kogenate",
                "designated_date": "1989-09-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)",
                "marketing_approval_date": "1993-02-25",
                "exclusivity_end_date": "2000-02-25",
                "sponsor": "Bayer Corporation|1884 Miles Avenue|Elkhart|Indiana|46515|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.",
                    "umls": "C0019069",
                    "parsed_text": "Hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "46506209",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46506209,
                "generic_name": "Antihemophilic factor (recombinant)",
                "trade_name": "ReFacto, Xyntha",
                "designated_date": "1996-02-08",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "2000-03-06",
                "sponsor": "Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Philadelphia|Pennsylvania|19101|United States",
                "orphan_designation": {
                    "original_text": "For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).",
                    "umls": [
                        "C0019069",
                        "C2674164"
                    ],
                    "parsed_text": [
                        "Hemophilia A",
                        "Hemorrhagic episodes"
                    ]
                }
            },
            {
                "pubchem_sid": 46506209,
                "generic_name": "Antihemophilic factor (recombinant)",
                "trade_name": "Kogenate",
                "designated_date": "1989-09-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)",
                "marketing_approval_date": "1993-02-25",
                "exclusivity_end_date": "2000-02-25",
                "sponsor": "Bayer Corporation|1884 Miles Avenue|Elkhart|Indiana|46515|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.",
                    "umls": "C0019069",
                    "parsed_text": "Hemophilia A"
                }
            }
        ]
    },
    {
        "_id": "347911209",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911209,
                "generic_name": "Antithrombin III (human)",
                "trade_name": "Thrombate III",
                "designated_date": "1984-11-26",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1991-12-30",
                "exclusivity_end_date": "1998-12-30",
                "sponsor": "Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.",
                    "umls": "C0333006",
                    "parsed_text": "congenital deficiency"
                }
            },
            {
                "pubchem_sid": 347911209,
                "generic_name": "Antithrombin III (human)",
                "trade_name": "ATnativ",
                "designated_date": "1985-02-08",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1989-12-13",
                "exclusivity_end_date": "1996-12-13",
                "sponsor": "Pharmacia & Upjohn AB|Lindhagensgatan 133|Stockholm|Sweden",
                "orphan_designation": {
                    "original_text": "For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.",
                    "umls": [
                        "C0040038",
                        "C2586031"
                    ],
                    "parsed_text": [
                        "Thromboembolism",
                        "Hereditary antithrombin III deficiency"
                    ]
                }
            },
            {
                "pubchem_sid": 347911209,
                "generic_name": "Antithrombin III human",
                "designated_date": "1986-01-02",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American National Red Cross|9312 Old Georgetown Road|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.",
                    "umls": [
                        "C0302148",
                        "C3714660"
                    ],
                    "parsed_text": [
                        "Thrombosis",
                        "Trauma"
                    ]
                }
            }
        ]
    },
    {
        "_id": "135346995",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135346995,
                "generic_name": "Antithrombin III (human)",
                "trade_name": "Thrombate III",
                "designated_date": "1984-11-26",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1991-12-30",
                "exclusivity_end_date": "1998-12-30",
                "sponsor": "Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States",
                "orphan_designation": {
                    "original_text": "For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.",
                    "umls": "C0333006",
                    "parsed_text": "congenital deficiency"
                }
            },
            {
                "pubchem_sid": 135346995,
                "generic_name": "Antithrombin III (human)",
                "trade_name": "ATnativ",
                "designated_date": "1985-02-08",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1989-12-13",
                "exclusivity_end_date": "1996-12-13",
                "sponsor": "Pharmacia & Upjohn AB|Lindhagensgatan 133|Stockholm|Sweden",
                "orphan_designation": {
                    "original_text": "For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.",
                    "umls": [
                        "C0040038",
                        "C2586031"
                    ],
                    "parsed_text": [
                        "Thromboembolism",
                        "Hereditary antithrombin III deficiency"
                    ]
                }
            },
            {
                "pubchem_sid": 135346995,
                "generic_name": "Antithrombin III human",
                "designated_date": "1986-01-02",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American National Red Cross|9312 Old Georgetown Road|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.",
                    "umls": [
                        "C0302148",
                        "C3714660"
                    ],
                    "parsed_text": [
                        "Thrombosis",
                        "Trauma"
                    ]
                }
            }
        ]
    },
    {
        "_id": "160693080",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160693080,
                "generic_name": "Antithrombin III human",
                "designated_date": "1986-01-02",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "American National Red Cross|9312 Old Georgetown Road|Bethesda|Maryland|20814|United States",
                "orphan_designation": {
                    "original_text": "Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.",
                    "umls": [
                        "C0302148",
                        "C3714660"
                    ],
                    "parsed_text": [
                        "Thrombosis",
                        "Trauma"
                    ]
                }
            }
        ]
    },
    {
        "_id": "404771575",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404771575,
                "generic_name": "Antivenin crotaline (pit-viper) equine immune F(ab)2)",
                "trade_name": "Anavip",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Management of adult and pediatric patients with North American rattlesnake envenomation",
                "marketing_approval_date": "2015-05-06",
                "exclusivity_end_date": "2022-05-06",
                "exclusivity_protected_indication": "Management of adult and pediatric patients with North American rattlesnake envenomation",
                "sponsor": "Rare Disease Therapeutics, Inc.|12975 Brookprinter Place|Suite 170|Poway|California|92064|United States",
                "orphan_designation": {
                    "original_text": "Treatment of envenomation by Crotaline snakes",
                    "umls": "C0040533",
                    "parsed_text": "Envenomation"
                }
            }
        ]
    },
    {
        "_id": "404859132",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404859132,
                "generic_name": "apraglutide",
                "designated_date": "2018-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of short bowel syndrome (SBS)",
                    "umls": "C0036992",
                    "parsed_text": "Short Bowel Syndrome"
                }
            }
        ]
    },
    {
        "_id": "384061881",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384061881,
                "generic_name": "apraglutide",
                "designated_date": "2018-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of short bowel syndrome (SBS)",
                    "umls": "C0036992",
                    "parsed_text": "Short Bowel Syndrome"
                }
            }
        ]
    },
    {
        "_id": "384060674",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384060674,
                "generic_name": "apraglutide",
                "designated_date": "2018-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of short bowel syndrome (SBS)",
                    "umls": "C0036992",
                    "parsed_text": "Short Bowel Syndrome"
                }
            }
        ]
    },
    {
        "_id": "381126894",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381126894,
                "generic_name": "apraglutide",
                "designated_date": "2018-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland",
                "orphan_designation": {
                    "original_text": "Treatment of short bowel syndrome (SBS)",
                    "umls": "C0036992",
                    "parsed_text": "Short Bowel Syndrome"
                }
            }
        ]
    },
    {
        "_id": "160671599",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160671599,
                "generic_name": "Arcitumomab",
                "designated_date": "1996-05-10",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",
                    "umls": "C0238462",
                    "parsed_text": "Medullary thyroid carcinoma"
                }
            }
        ]
    },
    {
        "_id": "135345795",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135345795,
                "generic_name": "Arcitumomab",
                "designated_date": "1996-05-10",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",
                    "umls": "C0238462",
                    "parsed_text": "Medullary thyroid carcinoma"
                }
            }
        ]
    },
    {
        "_id": "131277390",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 131277390,
                "generic_name": "Arcitumomab",
                "designated_date": "1996-05-10",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",
                    "umls": "C0238462",
                    "parsed_text": "Medullary thyroid carcinoma"
                }
            }
        ]
    },
    {
        "_id": "50070172",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50070172,
                "generic_name": "Arcitumomab",
                "designated_date": "1996-05-10",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States",
                "orphan_designation": {
                    "original_text": "Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",
                    "umls": "C0238462",
                    "parsed_text": "Medullary thyroid carcinoma"
                }
            }
        ]
    },
    {
        "_id": "381128718",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381128718,
                "generic_name": "Arenegyr",
                "designated_date": "2008-08-22",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MolMed S.p.A.|Via Olgettina 58|Milan|Italy",
                "orphan_designation": {
                    "original_text": "Treatment of malignant pleural mesothelioma",
                    "umls": "C0812413",
                    "parsed_text": "Malignant Pleural Mesothelioma"
                }
            }
        ]
    },
    {
        "_id": "381126438",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381126438,
                "generic_name": "Asfotase alfa",
                "trade_name": "Strensiq",
                "designated_date": "2008-09-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)",
                "marketing_approval_date": "2015-10-23",
                "exclusivity_end_date": "2022-10-23",
                "exclusivity_protected_indication": "For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)",
                "sponsor": "Alexion Pharmaceuticals, Inc.|100 College St.|New Haven|Connecticut|6510|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypophosphatasia",
                    "umls": "C0020630",
                    "parsed_text": "Hypophosphatasia"
                }
            }
        ]
    },
    {
        "_id": "347910406",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910406,
                "generic_name": "Asfotase alfa",
                "trade_name": "Strensiq",
                "designated_date": "2008-09-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)",
                "marketing_approval_date": "2015-10-23",
                "exclusivity_end_date": "2022-10-23",
                "exclusivity_protected_indication": "For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)",
                "sponsor": "Alexion Pharmaceuticals, Inc.|100 College St.|New Haven|Connecticut|6510|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypophosphatasia",
                    "umls": "C0020630",
                    "parsed_text": "Hypophosphatasia"
                }
            }
        ]
    },
    {
        "_id": "160682278",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160682278,
                "generic_name": "Asfotase alfa",
                "trade_name": "Strensiq",
                "designated_date": "2008-09-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)",
                "marketing_approval_date": "2015-10-23",
                "exclusivity_end_date": "2022-10-23",
                "exclusivity_protected_indication": "For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)",
                "sponsor": "Alexion Pharmaceuticals, Inc.|100 College St.|New Haven|Connecticut|6510|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypophosphatasia",
                    "umls": "C0020630",
                    "parsed_text": "Hypophosphatasia"
                }
            }
        ]
    },
    {
        "_id": "404772371",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772371,
                "generic_name": "astuprotimut-R",
                "designated_date": "2009-05-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline Biologicals, S.A.|Rue de I'Institut 89|B-1330 Rixensart|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of MAGE-A3 positive non-small cell lung cancer",
                    "umls": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "pubchem_sid": 404772371,
                "generic_name": "astuprotimut-R",
                "designated_date": "2009-05-29",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline Biologicals, S.A.|Rue de l'Institut 89|B-1330 Rixensart|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma",
                    "umls": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            }
        ]
    },
    {
        "_id": "160693090",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160693090,
                "generic_name": "astuprotimut-R",
                "designated_date": "2009-05-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline Biologicals, S.A.|Rue de I'Institut 89|B-1330 Rixensart|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of MAGE-A3 positive non-small cell lung cancer",
                    "umls": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "pubchem_sid": 160693090,
                "generic_name": "astuprotimut-R",
                "designated_date": "2009-05-29",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline Biologicals, S.A.|Rue de l'Institut 89|B-1330 Rixensart|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma",
                    "umls": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            }
        ]
    },
    {
        "_id": "135342748",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135342748,
                "generic_name": "astuprotimut-R",
                "designated_date": "2009-05-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline Biologicals, S.A.|Rue de I'Institut 89|B-1330 Rixensart|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of MAGE-A3 positive non-small cell lung cancer",
                    "umls": "C3539721",
                    "parsed_text": "Non-Small Cell Lung Cancer"
                }
            },
            {
                "pubchem_sid": 135342748,
                "generic_name": "astuprotimut-R",
                "designated_date": "2009-05-29",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "GlaxoSmithKline Biologicals, S.A.|Rue de l'Institut 89|B-1330 Rixensart|Belgium",
                "orphan_designation": {
                    "original_text": "Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma",
                    "umls": "C0025202",
                    "parsed_text": "Malignant Melanoma"
                }
            }
        ]
    },
    {
        "_id": "387061104",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387061104,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 387061104,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 387061104,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 387061104,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 387061104,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "385327550",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 385327550,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 385327550,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 385327550,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 385327550,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 385327550,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "384647093",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384647093,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 384647093,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 384647093,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 384647093,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 384647093,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "377483935",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 377483935,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 377483935,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 377483935,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 377483935,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 377483935,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "354355059",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 354355059,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 354355059,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 354355059,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 354355059,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 354355059,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "347911207",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911207,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 347911207,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 347911207,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 347911207,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 347911207,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "318464470",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 318464470,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 318464470,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 318464470,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 318464470,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 318464470,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "249565671",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 249565671,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2016-10-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "marketing_approval_date": "2019-03-18",
                "exclusivity_end_date": "2026-03-18",
                "exclusivity_protected_indication": "TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of small cell lung cancer (SCLC)",
                    "umls": [
                        "C0149925",
                        "C0262584",
                        "C3540630"
                    ],
                    "parsed_text": [
                        "Small Cell Lung Cancer",
                        "SCLC",
                        "Small Cell Lung Cancer"
                    ]
                }
            },
            {
                "pubchem_sid": 249565671,
                "generic_name": "Atezolizumab",
                "designated_date": "2020-10-08",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "treatment of soft tissue sarcoma",
                    "umls": "C1261473",
                    "parsed_text": "Soft tissue sarcoma"
                }
            },
            {
                "pubchem_sid": 249565671,
                "generic_name": "Atezolizumab",
                "designated_date": "2021-01-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States",
                "orphan_designation": {
                    "original_text": "Treatment of esophageal cancer",
                    "umls": "C0014859",
                    "parsed_text": "esophageal cancer"
                }
            },
            {
                "pubchem_sid": 249565671,
                "generic_name": "atezolizumab",
                "trade_name": "TECENTRIQ",
                "designated_date": "2017-02-13",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "marketing_approval_date": "2020-07-30",
                "exclusivity_end_date": "2027-07-30",
                "exclusivity_protected_indication": "indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage llb, llc, lll and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            },
            {
                "pubchem_sid": 249565671,
                "generic_name": "Atezolizumab",
                "designated_date": "2017-02-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with stage IIb, IIc, III, and IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "440234488",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440234488,
                "generic_name": "autologous umbilical cord blood",
                "designated_date": "2012-07-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Duke University|2301 Erwin Road|Durham|North Carolina|27710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury",
                    "umls": [
                        "C0007789",
                        "C0270611"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Brain Injury"
                    ]
                }
            }
        ]
    },
    {
        "_id": "440234715",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440234715,
                "generic_name": "avalglucosidase alfa",
                "designated_date": "2013-11-19",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme, a Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pompe Disease",
                    "umls": "C0017921",
                    "parsed_text": "Pompe Disease"
                }
            }
        ]
    },
    {
        "_id": "381128032",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381128032,
                "generic_name": "avalglucosidase alfa",
                "designated_date": "2013-11-19",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genzyme, a Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Pompe Disease",
                    "umls": "C0017921",
                    "parsed_text": "Pompe Disease"
                }
            }
        ]
    },
    {
        "_id": "381127599",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381127599,
                "generic_name": "avelumab",
                "designated_date": "2017-10-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)",
                    "umls": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "355203157",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 355203157,
                "generic_name": "avelumab",
                "designated_date": "2017-10-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)",
                    "umls": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "355203045",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 355203045,
                "generic_name": "avelumab",
                "designated_date": "2017-10-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)",
                    "umls": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "347911260",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911260,
                "generic_name": "avelumab",
                "designated_date": "2017-10-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)",
                    "umls": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "336908606",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 336908606,
                "generic_name": "avelumab",
                "designated_date": "2017-10-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)",
                    "umls": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "252827393",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 252827393,
                "generic_name": "avelumab",
                "designated_date": "2017-10-11",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States",
                "orphan_designation": {
                    "original_text": "Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ)",
                    "umls": "C0024623",
                    "parsed_text": "Gastric Cancer"
                }
            }
        ]
    },
    {
        "_id": "440234879",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440234879,
                "generic_name": "axatilimab",
                "designated_date": "2021-04-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Building D, Floor 3|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Idiopathic Pulmonary Fibrosis",
                    "umls": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "pubchem_sid": 440234879,
                "generic_name": "axatilimab",
                "designated_date": "2021-03-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic graft versus host disease.",
                    "umls": "C0867389",
                    "parsed_text": "Chronic Graft Versus Host Disease"
                }
            }
        ]
    },
    {
        "_id": "402425985",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 402425985,
                "generic_name": "axatilimab",
                "designated_date": "2021-04-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Building D, Floor 3|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Idiopathic Pulmonary Fibrosis",
                    "umls": "C1800706",
                    "parsed_text": "Idiopathic Pulmonary Fibrosis"
                }
            },
            {
                "pubchem_sid": 402425985,
                "generic_name": "axatilimab",
                "designated_date": "2021-03-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Waltham|Massachusetts|2451|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic graft versus host disease.",
                    "umls": "C0867389",
                    "parsed_text": "Chronic Graft Versus Host Disease"
                }
            }
        ]
    },
    {
        "_id": "381129647",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381129647,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary mediastinal B-cell lymphoma.",
                    "umls": "C0079731",
                    "parsed_text": "B-Cell Lymphoma"
                }
            },
            {
                "pubchem_sid": 381129647,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma.",
                    "umls": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "pubchem_sid": 381129647,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2014-03-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "pubchem_sid": 381129647,
                "generic_name": "axicabtagene ciloleucel",
                "designated_date": "2020-03-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "pubchem_sid": 381129647,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy",
                "marketing_approval_date": "2021-03-05",
                "sponsor": "Kite Pharma Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma.",
                    "umls": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "pubchem_sid": 381129647,
                "generic_name": "axicabtagene ciloleucel",
                "designated_date": "2020-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma",
                    "umls": "C1367654",
                    "parsed_text": "Marginal zone lymphoma"
                }
            }
        ]
    },
    {
        "_id": "374364294",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 374364294,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary mediastinal B-cell lymphoma.",
                    "umls": "C0079731",
                    "parsed_text": "B-Cell Lymphoma"
                }
            },
            {
                "pubchem_sid": 374364294,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma.",
                    "umls": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "pubchem_sid": 374364294,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2014-03-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "pubchem_sid": 374364294,
                "generic_name": "axicabtagene ciloleucel",
                "designated_date": "2020-03-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "pubchem_sid": 374364294,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy",
                "marketing_approval_date": "2021-03-05",
                "sponsor": "Kite Pharma Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma.",
                    "umls": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "pubchem_sid": 374364294,
                "generic_name": "axicabtagene ciloleucel",
                "designated_date": "2020-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma",
                    "umls": "C1367654",
                    "parsed_text": "Marginal zone lymphoma"
                }
            }
        ]
    },
    {
        "_id": "347911476",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911476,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary mediastinal B-cell lymphoma.",
                    "umls": "C0079731",
                    "parsed_text": "B-Cell Lymphoma"
                }
            },
            {
                "pubchem_sid": 347911476,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma.",
                    "umls": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "pubchem_sid": 347911476,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2014-03-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",
                "marketing_approval_date": "2017-10-18",
                "exclusivity_end_date": "2024-10-18",
                "exclusivity_protected_indication": "Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma",
                "sponsor": "Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of diffuse large B-cell lymphoma",
                    "umls": "C1332201",
                    "parsed_text": "Diffuse Large B-Cell Lymphoma"
                }
            },
            {
                "pubchem_sid": 347911476,
                "generic_name": "axicabtagene ciloleucel",
                "designated_date": "2020-03-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of nodal marginal zone lymphoma",
                    "umls": "C0242647",
                    "parsed_text": "Nodal marginal zone lymphoma"
                }
            },
            {
                "pubchem_sid": 347911476,
                "generic_name": "axicabtagene ciloleucel",
                "trade_name": "Yescarta",
                "designated_date": "2016-04-25",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy",
                "marketing_approval_date": "2021-03-05",
                "sponsor": "Kite Pharma Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of follicular lymphoma.",
                    "umls": "C0024301",
                    "parsed_text": "follicular lymphoma"
                }
            },
            {
                "pubchem_sid": 347911476,
                "generic_name": "axicabtagene ciloleucel",
                "designated_date": "2020-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extranodal marginal zone lymphoma",
                    "umls": "C1367654",
                    "parsed_text": "Marginal zone lymphoma"
                }
            }
        ]
    },
    {
        "_id": "381125720",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381125720,
                "generic_name": "Azurin-p28",
                "designated_date": "2015-12-02",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "CDG Therapeutics, Inc.|840 South Wood Street|M/C 820|Chicago|Illinois|60612|United States",
                "orphan_designation": {
                    "original_text": "Treatment of glioma",
                    "umls": "C0017638",
                    "parsed_text": "Glioma"
                }
            }
        ]
    },
    {
        "_id": "160693120",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160693120,
                "generic_name": "Bacillus Calmette-Guerin vaccine",
                "designated_date": "2006-08-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "OncoVac Corporation|P. O. Box 970|Pacific Palisades|California|90272|United States",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIb through IV metastatic melanoma",
                    "umls": "C0278883",
                    "parsed_text": "Metastatic melanoma"
                }
            }
        ]
    },
    {
        "_id": "441073676",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 441073676,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "440701517",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440701517,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "440064057",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440064057,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "439508002",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 439508002,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "438644584",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 438644584,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "438536569",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 438536569,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "405235684",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 405235684,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "404614577",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404614577,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "387113800",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387113800,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "385840929",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 385840929,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "385834696",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 385834696,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "384385661",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384385661,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "383548014",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 383548014,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "381395584",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381395584,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "377311345",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 377311345,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "376051446",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 376051446,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "348746094",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 348746094,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "348397129",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 348397129,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "347913992",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347913992,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "347636808",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347636808,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "342544612",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 342544612,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "340507965",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 340507965,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "318153988",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 318153988,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "313075802",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 313075802,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "176331282",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 176331282,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "162224794",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 162224794,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "50071585",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50071585,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "50071584",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50071584,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "50071583",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50071583,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "49873563",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 49873563,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "605350",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 605350,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "4814",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 4814,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "387079919",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387079919,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "377014793",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 377014793,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "404425800",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404425800,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "387079921",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387079921,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "387079920",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387079920,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "316962251",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 316962251,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "315444088",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 315444088,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "252402155",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 252402155,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "144206731",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 144206731,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "144204057",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 144204057,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "144074916",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 144074916,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "126676473",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 126676473,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "546764",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 546764,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "440790689",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790689,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "438474345",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 438474345,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "406582657",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 406582657,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "374155019",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 374155019,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "346444061",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 346444061,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "335958847",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 335958847,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "318238404",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 318238404,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "316898684",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 316898684,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "254759847",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 254759847,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "204380020",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 204380020,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "196105735",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 196105735,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "163814587",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 163814587,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "126655275",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 126655275,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "126629464",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 126629464,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "440681435",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440681435,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "387166216",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387166216,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "376227004",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 376227004,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "341139910",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 341139910,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "268734448",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 268734448,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "162228041",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 162228041,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "124766072",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 124766072,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "103914703",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103914703,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "52518470",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 52518470,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "8149211",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 8149211,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "434131544",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 434131544,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "373567635",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 373567635,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "310267241",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 310267241,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "162180419",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 162180419,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "52518469",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 52518469,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "7978755",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 7978755,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "438451119",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 438451119,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "434142455",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 434142455,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "433925319",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 433925319,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "350086297",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 350086297,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "349989661",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349989661,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "348283279",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 348283279,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "347673985",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347673985,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "312693845",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 312693845,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "312228282",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 312228282,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "224054832",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 224054832,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "134981168",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 134981168,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "103770541",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103770541,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "99381480",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 99381480,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "46504727",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46504727,
                "generic_name": "Bacitracin",
                "designated_date": "1984-03-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States",
                "orphan_designation": {
                    "original_text": "Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.",
                    "umls": "C0014358",
                    "parsed_text": "Pseudomembranous enterocolitis"
                }
            }
        ]
    },
    {
        "_id": "440790690",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790690,
                "generic_name": "Basiliximab",
                "trade_name": "Simulect",
                "designated_date": "1997-12-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",
                "marketing_approval_date": "1998-05-12",
                "exclusivity_end_date": "2005-05-12",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of solid organ rejection.",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "178103461",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103461,
                "generic_name": "Basiliximab",
                "trade_name": "Simulect",
                "designated_date": "1997-12-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",
                "marketing_approval_date": "1998-05-12",
                "exclusivity_end_date": "2005-05-12",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of solid organ rejection.",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "135321271",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135321271,
                "generic_name": "Basiliximab",
                "trade_name": "Simulect",
                "designated_date": "1997-12-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",
                "marketing_approval_date": "1998-05-12",
                "exclusivity_end_date": "2005-05-12",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of solid organ rejection.",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "103771251",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771251,
                "generic_name": "Basiliximab",
                "trade_name": "Simulect",
                "designated_date": "1997-12-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",
                "marketing_approval_date": "1998-05-12",
                "exclusivity_end_date": "2005-05-12",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of solid organ rejection.",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "50067184",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50067184,
                "generic_name": "Basiliximab",
                "trade_name": "Simulect",
                "designated_date": "1997-12-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",
                "marketing_approval_date": "1998-05-12",
                "exclusivity_end_date": "2005-05-12",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of solid organ rejection.",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "46505169",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46505169,
                "generic_name": "Basiliximab",
                "trade_name": "Simulect",
                "designated_date": "1997-12-12",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",
                "marketing_approval_date": "1998-05-12",
                "exclusivity_end_date": "2005-05-12",
                "sponsor": "Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of solid organ rejection.",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "434122177",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 434122177,
                "generic_name": "belantamab mafodotin-blmf",
                "trade_name": "BLENREP",
                "designated_date": "2017-06-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",
                "marketing_approval_date": "2020-08-05",
                "exclusivity_end_date": "2027-08-05",
                "exclusivity_protected_indication": "for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",
                "sponsor": "GlaxoSmithKline Intellectual Property Development Ltd.|980 GREAT WEST ROAD|BRENTFORD|MIDDLESEX|TW89GS|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "405226462",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 405226462,
                "generic_name": "belantamab mafodotin-blmf",
                "trade_name": "BLENREP",
                "designated_date": "2017-06-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",
                "marketing_approval_date": "2020-08-05",
                "exclusivity_end_date": "2027-08-05",
                "exclusivity_protected_indication": "for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",
                "sponsor": "GlaxoSmithKline Intellectual Property Development Ltd.|980 GREAT WEST ROAD|BRENTFORD|MIDDLESEX|TW89GS|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "404719842",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404719842,
                "generic_name": "belantamab mafodotin-blmf",
                "trade_name": "BLENREP",
                "designated_date": "2017-06-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",
                "marketing_approval_date": "2020-08-05",
                "exclusivity_end_date": "2027-08-05",
                "exclusivity_protected_indication": "for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",
                "sponsor": "GlaxoSmithKline Intellectual Property Development Ltd.|980 GREAT WEST ROAD|BRENTFORD|MIDDLESEX|TW89GS|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of multiple myeloma",
                    "umls": "C0026764",
                    "parsed_text": "Multiple Myeloma"
                }
            }
        ]
    },
    {
        "_id": "347910359",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910359,
                "generic_name": "belatacept",
                "trade_name": "Nulojix",
                "designated_date": "2008-02-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of organ rejection in adult patients receiving kidney transplants",
                "marketing_approval_date": "2011-06-15",
                "exclusivity_end_date": "2018-06-15",
                "sponsor": "Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in renal allograft recipients",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "178103474",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103474,
                "generic_name": "belatacept",
                "trade_name": "Nulojix",
                "designated_date": "2008-02-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of organ rejection in adult patients receiving kidney transplants",
                "marketing_approval_date": "2011-06-15",
                "exclusivity_end_date": "2018-06-15",
                "sponsor": "Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in renal allograft recipients",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "135283321",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135283321,
                "generic_name": "belatacept",
                "trade_name": "Nulojix",
                "designated_date": "2008-02-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of organ rejection in adult patients receiving kidney transplants",
                "marketing_approval_date": "2011-06-15",
                "exclusivity_end_date": "2018-06-15",
                "sponsor": "Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in renal allograft recipients",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "131287524",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 131287524,
                "generic_name": "belatacept",
                "trade_name": "Nulojix",
                "designated_date": "2008-02-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prophylaxis of organ rejection in adult patients receiving kidney transplants",
                "marketing_approval_date": "2011-06-15",
                "exclusivity_end_date": "2018-06-15",
                "sponsor": "Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States",
                "orphan_designation": {
                    "original_text": "Prophylaxis of organ rejection in renal allograft recipients",
                    "umls": "C0815080",
                    "parsed_text": "organ rejection"
                }
            }
        ]
    },
    {
        "_id": "404859106",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404859106,
                "generic_name": "bempegaldesleukin",
                "designated_date": "2020-04-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIb to Stage IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "404772580",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772580,
                "generic_name": "bempegaldesleukin",
                "designated_date": "2020-04-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIb to Stage IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "404720042",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404720042,
                "generic_name": "bempegaldesleukin",
                "designated_date": "2020-04-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIb to Stage IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "381128181",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381128181,
                "generic_name": "bempegaldesleukin",
                "designated_date": "2020-04-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Stage IIb to Stage IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "402356184",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 402356184,
                "generic_name": "benralizumab",
                "designated_date": "2019-08-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "pubchem_sid": 402356184,
                "generic_name": "benralizumab",
                "designated_date": "2018-11-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic granulomatosis with polyangiitis",
                    "umls": "C0008728",
                    "parsed_text": "Eosinophilic granulomatosis with polyangiitis"
                }
            },
            {
                "pubchem_sid": 402356184,
                "generic_name": "benralizumab",
                "designated_date": "2019-02-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypereosinophilic syndrome",
                    "umls": "C1540912",
                    "parsed_text": "Hypereosinophilic syndrome"
                }
            }
        ]
    },
    {
        "_id": "402355846",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 402355846,
                "generic_name": "benralizumab",
                "designated_date": "2019-08-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "pubchem_sid": 402355846,
                "generic_name": "benralizumab",
                "designated_date": "2018-11-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic granulomatosis with polyangiitis",
                    "umls": "C0008728",
                    "parsed_text": "Eosinophilic granulomatosis with polyangiitis"
                }
            },
            {
                "pubchem_sid": 402355846,
                "generic_name": "benralizumab",
                "designated_date": "2019-02-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypereosinophilic syndrome",
                    "umls": "C1540912",
                    "parsed_text": "Hypereosinophilic syndrome"
                }
            }
        ]
    },
    {
        "_id": "347911271",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911271,
                "generic_name": "benralizumab",
                "designated_date": "2019-08-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "pubchem_sid": 347911271,
                "generic_name": "benralizumab",
                "designated_date": "2018-11-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic granulomatosis with polyangiitis",
                    "umls": "C0008728",
                    "parsed_text": "Eosinophilic granulomatosis with polyangiitis"
                }
            },
            {
                "pubchem_sid": 347911271,
                "generic_name": "benralizumab",
                "designated_date": "2019-02-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypereosinophilic syndrome",
                    "umls": "C1540912",
                    "parsed_text": "Hypereosinophilic syndrome"
                }
            }
        ]
    },
    {
        "_id": "223366009",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 223366009,
                "generic_name": "benralizumab",
                "designated_date": "2019-08-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "pubchem_sid": 223366009,
                "generic_name": "benralizumab",
                "designated_date": "2018-11-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic granulomatosis with polyangiitis",
                    "umls": "C0008728",
                    "parsed_text": "Eosinophilic granulomatosis with polyangiitis"
                }
            },
            {
                "pubchem_sid": 223366009,
                "generic_name": "benralizumab",
                "designated_date": "2019-02-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypereosinophilic syndrome",
                    "umls": "C1540912",
                    "parsed_text": "Hypereosinophilic syndrome"
                }
            }
        ]
    },
    {
        "_id": "160704150",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160704150,
                "generic_name": "benralizumab",
                "designated_date": "2019-08-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "pubchem_sid": 160704150,
                "generic_name": "benralizumab",
                "designated_date": "2018-11-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic granulomatosis with polyangiitis",
                    "umls": "C0008728",
                    "parsed_text": "Eosinophilic granulomatosis with polyangiitis"
                }
            },
            {
                "pubchem_sid": 160704150,
                "generic_name": "benralizumab",
                "designated_date": "2019-02-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypereosinophilic syndrome",
                    "umls": "C1540912",
                    "parsed_text": "Hypereosinophilic syndrome"
                }
            }
        ]
    },
    {
        "_id": "135339902",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135339902,
                "generic_name": "benralizumab",
                "designated_date": "2019-08-26",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic esophagitis",
                    "umls": "C0341106",
                    "parsed_text": "Eosinophilic esophagitis"
                }
            },
            {
                "pubchem_sid": 135339902,
                "generic_name": "benralizumab",
                "designated_date": "2018-11-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of eosinophilic granulomatosis with polyangiitis",
                    "umls": "C0008728",
                    "parsed_text": "Eosinophilic granulomatosis with polyangiitis"
                }
            },
            {
                "pubchem_sid": 135339902,
                "generic_name": "benralizumab",
                "designated_date": "2019-02-01",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hypereosinophilic syndrome",
                    "umls": "C1540912",
                    "parsed_text": "Hypereosinophilic syndrome"
                }
            }
        ]
    },
    {
        "_id": "347910369",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910369,
                "generic_name": "Beractant",
                "designated_date": "1993-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",
                    "umls": [
                        "C0025048",
                        "C0031190",
                        "C0032285",
                        "C0243026",
                        "C1145670"
                    ],
                    "parsed_text": [
                        "Meconium Aspiration Syndrome",
                        "Persistent pulmonary hypertension of the newborn",
                        "Pneumonia",
                        "Sepsis",
                        "Respiratory Failure"
                    ]
                }
            },
            {
                "pubchem_sid": 347910369,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of (\"rescue\") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",
                "marketing_approval_date": "1991-07-01",
                "exclusivity_end_date": "1998-07-01",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            },
            {
                "pubchem_sid": 347910369,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency",
                "marketing_approval_date": "1991-07-02",
                "exclusivity_end_date": "1998-07-02",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            }
        ]
    },
    {
        "_id": "135335308",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135335308,
                "generic_name": "Beractant",
                "designated_date": "1993-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",
                    "umls": [
                        "C0025048",
                        "C0031190",
                        "C0032285",
                        "C0243026",
                        "C1145670"
                    ],
                    "parsed_text": [
                        "Meconium Aspiration Syndrome",
                        "Persistent pulmonary hypertension of the newborn",
                        "Pneumonia",
                        "Sepsis",
                        "Respiratory Failure"
                    ]
                }
            },
            {
                "pubchem_sid": 135335308,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of (\"rescue\") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",
                "marketing_approval_date": "1991-07-01",
                "exclusivity_end_date": "1998-07-01",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            },
            {
                "pubchem_sid": 135335308,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency",
                "marketing_approval_date": "1991-07-02",
                "exclusivity_end_date": "1998-07-02",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            }
        ]
    },
    {
        "_id": "103771378",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771378,
                "generic_name": "Beractant",
                "designated_date": "1993-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",
                    "umls": [
                        "C0025048",
                        "C0031190",
                        "C0032285",
                        "C0243026",
                        "C1145670"
                    ],
                    "parsed_text": [
                        "Meconium Aspiration Syndrome",
                        "Persistent pulmonary hypertension of the newborn",
                        "Pneumonia",
                        "Sepsis",
                        "Respiratory Failure"
                    ]
                }
            },
            {
                "pubchem_sid": 103771378,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of (\"rescue\") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",
                "marketing_approval_date": "1991-07-01",
                "exclusivity_end_date": "1998-07-01",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            },
            {
                "pubchem_sid": 103771378,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency",
                "marketing_approval_date": "1991-07-02",
                "exclusivity_end_date": "1998-07-02",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            }
        ]
    },
    {
        "_id": "53789802",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 53789802,
                "generic_name": "Beractant",
                "designated_date": "1993-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",
                    "umls": [
                        "C0025048",
                        "C0031190",
                        "C0032285",
                        "C0243026",
                        "C1145670"
                    ],
                    "parsed_text": [
                        "Meconium Aspiration Syndrome",
                        "Persistent pulmonary hypertension of the newborn",
                        "Pneumonia",
                        "Sepsis",
                        "Respiratory Failure"
                    ]
                }
            },
            {
                "pubchem_sid": 53789802,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of (\"rescue\") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",
                "marketing_approval_date": "1991-07-01",
                "exclusivity_end_date": "1998-07-01",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            },
            {
                "pubchem_sid": 53789802,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency",
                "marketing_approval_date": "1991-07-02",
                "exclusivity_end_date": "1998-07-02",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            }
        ]
    },
    {
        "_id": "50070149",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50070149,
                "generic_name": "Beractant",
                "designated_date": "1993-12-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",
                    "umls": [
                        "C0025048",
                        "C0031190",
                        "C0032285",
                        "C0243026",
                        "C1145670"
                    ],
                    "parsed_text": [
                        "Meconium Aspiration Syndrome",
                        "Persistent pulmonary hypertension of the newborn",
                        "Pneumonia",
                        "Sepsis",
                        "Respiratory Failure"
                    ]
                }
            },
            {
                "pubchem_sid": 50070149,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of (\"rescue\") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",
                "marketing_approval_date": "1991-07-01",
                "exclusivity_end_date": "1998-07-01",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            },
            {
                "pubchem_sid": 50070149,
                "generic_name": "Beractant",
                "trade_name": "Survanta intratracheal suspension",
                "designated_date": "1986-02-05",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency",
                "marketing_approval_date": "1991-07-02",
                "exclusivity_end_date": "1998-07-02",
                "sponsor": "Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States",
                "orphan_designation": {
                    "original_text": "Treatment of neonatal respiratory distress syndrome",
                    "umls": "C0035220",
                    "parsed_text": "Neonatal Respiratory Distress Syndrome"
                }
            }
        ]
    },
    {
        "_id": "349016377",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349016377,
                "generic_name": "bertilimumab",
                "designated_date": "2018-08-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bullous pemphigoid",
                    "umls": "C0030805",
                    "parsed_text": "Bullous pemphigoid"
                }
            }
        ]
    },
    {
        "_id": "160698501",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160698501,
                "generic_name": "bertilimumab",
                "designated_date": "2018-08-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bullous pemphigoid",
                    "umls": "C0030805",
                    "parsed_text": "Bullous pemphigoid"
                }
            }
        ]
    },
    {
        "_id": "135341000",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135341000,
                "generic_name": "bertilimumab",
                "designated_date": "2018-08-17",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States",
                "orphan_designation": {
                    "original_text": "Treatment of bullous pemphigoid",
                    "umls": "C0030805",
                    "parsed_text": "Bullous pemphigoid"
                }
            }
        ]
    },
    {
        "_id": "441072526",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 441072526,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "440790697",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 440790697,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "387061165",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 387061165,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "350080043",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 350080043,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "348480209",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 348480209,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "329976976",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 329976976,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "178103377",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 178103377,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "135329020",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 135329020,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "103771315",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 103771315,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "50067187",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 50067187,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "46504473",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "designated_date": "2004-10-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pancreatic cancer",
                    "umls": "C0235974",
                    "parsed_text": "PANCREATIC CANCER"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of fallopian tube carcinoma",
                    "umls": "C0238122",
                    "parsed_text": "Fallopian Tube Carcinoma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "designated_date": "2016-01-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mesothelioma",
                    "umls": "C0025500",
                    "parsed_text": "Mesothelioma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2010-11-02",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei",
                "marketing_approval_date": "2018-06-13",
                "exclusivity_end_date": "2025-06-13",
                "exclusivity_protected_indication": "In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of primary peritoneal carcinoma.",
                    "umls": "C1514428",
                    "parsed_text": "Primary peritoneal carcinoma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "designated_date": "2016-03-10",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of Coat's disease",
                    "umls": "C0154832",
                    "parsed_text": "coat's disease"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "designated_date": "2010-10-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hereditary hemorrhagic telangiectasia",
                    "umls": "C0039445",
                    "parsed_text": "hereditary hemorrhagic telangiectasia"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-05-26",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of glioblastoma with progressive disease following prior therapy",
                "marketing_approval_date": "2009-05-05",
                "exclusivity_end_date": "2016-05-05",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of malignant glioma",
                    "umls": "C0555198",
                    "parsed_text": "Malignant Glioma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",
                "marketing_approval_date": "2014-11-14",
                "exclusivity_end_date": "2021-11-14",
                "exclusivity_protected_indication": "In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2003-11-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of renal cell carcinoma in combination with interferon alfa",
                "marketing_approval_date": "2009-07-31",
                "exclusivity_end_date": "2016-07-31",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of renal cell carcinoma",
                    "umls": "C0007134",
                    "parsed_text": "Renal Cell Carcinoma"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "designated_date": "2009-11-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.",
                    "umls": "C0024623",
                    "parsed_text": "stomach cancer"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "trade_name": "Avastin",
                "designated_date": "2006-02-09",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi",
                "marketing_approval_date": "2016-12-06",
                "exclusivity_end_date": "2023-12-06",
                "exclusivity_protected_indication": "Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Therapeutic treatment of patients with ovarian cancer",
                    "umls": "C4721610",
                    "parsed_text": "Ovarian Cancer"
                }
            },
            {
                "pubchem_sid": 46504473,
                "generic_name": "bevacizumab",
                "designated_date": "2009-10-13",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen",
                    "umls": "C0280209",
                    "parsed_text": "melanoma stages"
                }
            }
        ]
    },
    {
        "_id": "440790701",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790701,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1991-12-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 440790701,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-30",
                "exclusivity_end_date": "1996-12-30",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            },
            {
                "pubchem_sid": 440790701,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Dysport",
                "designated_date": "1999-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lower limb spasticity in pediatric patients 2 years of age and older",
                "marketing_approval_date": "2016-07-29",
                "exclusivity_end_date": "2023-07-29",
                "exclusivity_protected_indication": "Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Contractures"
                    ]
                }
            },
            {
                "pubchem_sid": 440790701,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1989-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 440790701,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1986-08-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.",
                "marketing_approval_date": "2000-12-21",
                "exclusivity_end_date": "2007-12-21",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical dystonia.",
                    "umls": "C0152116",
                    "parsed_text": "Cervical Dystonia"
                }
            },
            {
                "pubchem_sid": 440790701,
                "generic_name": "botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1991-12-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.",
                "marketing_approval_date": "2019-06-20",
                "exclusivity_end_date": "2026-06-20",
                "exclusivity_protected_indication": "For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Muscle contracture"
                    ]
                }
            },
            {
                "pubchem_sid": 440790701,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1998-08-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            },
            {
                "pubchem_sid": 440790701,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-29",
                "exclusivity_end_date": "1996-12-29",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            }
        ]
    },
    {
        "_id": "404720407",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404720407,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1991-12-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 404720407,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-30",
                "exclusivity_end_date": "1996-12-30",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            },
            {
                "pubchem_sid": 404720407,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Dysport",
                "designated_date": "1999-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lower limb spasticity in pediatric patients 2 years of age and older",
                "marketing_approval_date": "2016-07-29",
                "exclusivity_end_date": "2023-07-29",
                "exclusivity_protected_indication": "Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Contractures"
                    ]
                }
            },
            {
                "pubchem_sid": 404720407,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1989-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 404720407,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1986-08-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.",
                "marketing_approval_date": "2000-12-21",
                "exclusivity_end_date": "2007-12-21",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical dystonia.",
                    "umls": "C0152116",
                    "parsed_text": "Cervical Dystonia"
                }
            },
            {
                "pubchem_sid": 404720407,
                "generic_name": "botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1991-12-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.",
                "marketing_approval_date": "2019-06-20",
                "exclusivity_end_date": "2026-06-20",
                "exclusivity_protected_indication": "For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Muscle contracture"
                    ]
                }
            },
            {
                "pubchem_sid": 404720407,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1998-08-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            },
            {
                "pubchem_sid": 404720407,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-29",
                "exclusivity_end_date": "1996-12-29",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            }
        ]
    },
    {
        "_id": "135351517",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135351517,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1991-12-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 135351517,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-30",
                "exclusivity_end_date": "1996-12-30",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            },
            {
                "pubchem_sid": 135351517,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Dysport",
                "designated_date": "1999-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lower limb spasticity in pediatric patients 2 years of age and older",
                "marketing_approval_date": "2016-07-29",
                "exclusivity_end_date": "2023-07-29",
                "exclusivity_protected_indication": "Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Contractures"
                    ]
                }
            },
            {
                "pubchem_sid": 135351517,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1989-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 135351517,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1986-08-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.",
                "marketing_approval_date": "2000-12-21",
                "exclusivity_end_date": "2007-12-21",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical dystonia.",
                    "umls": "C0152116",
                    "parsed_text": "Cervical Dystonia"
                }
            },
            {
                "pubchem_sid": 135351517,
                "generic_name": "botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1991-12-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.",
                "marketing_approval_date": "2019-06-20",
                "exclusivity_end_date": "2026-06-20",
                "exclusivity_protected_indication": "For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Muscle contracture"
                    ]
                }
            },
            {
                "pubchem_sid": 135351517,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1998-08-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            },
            {
                "pubchem_sid": 135351517,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-29",
                "exclusivity_end_date": "1996-12-29",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            }
        ]
    },
    {
        "_id": "81065599",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 81065599,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1991-12-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 81065599,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-30",
                "exclusivity_end_date": "1996-12-30",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            },
            {
                "pubchem_sid": 81065599,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Dysport",
                "designated_date": "1999-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lower limb spasticity in pediatric patients 2 years of age and older",
                "marketing_approval_date": "2016-07-29",
                "exclusivity_end_date": "2023-07-29",
                "exclusivity_protected_indication": "Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Contractures"
                    ]
                }
            },
            {
                "pubchem_sid": 81065599,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1989-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 81065599,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1986-08-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.",
                "marketing_approval_date": "2000-12-21",
                "exclusivity_end_date": "2007-12-21",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical dystonia.",
                    "umls": "C0152116",
                    "parsed_text": "Cervical Dystonia"
                }
            },
            {
                "pubchem_sid": 81065599,
                "generic_name": "botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1991-12-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.",
                "marketing_approval_date": "2019-06-20",
                "exclusivity_end_date": "2026-06-20",
                "exclusivity_protected_indication": "For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Muscle contracture"
                    ]
                }
            },
            {
                "pubchem_sid": 81065599,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1998-08-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            },
            {
                "pubchem_sid": 81065599,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-29",
                "exclusivity_end_date": "1996-12-29",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            }
        ]
    },
    {
        "_id": "49895113",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 49895113,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1991-12-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 49895113,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-30",
                "exclusivity_end_date": "1996-12-30",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            },
            {
                "pubchem_sid": 49895113,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Dysport",
                "designated_date": "1999-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lower limb spasticity in pediatric patients 2 years of age and older",
                "marketing_approval_date": "2016-07-29",
                "exclusivity_end_date": "2023-07-29",
                "exclusivity_protected_indication": "Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Contractures"
                    ]
                }
            },
            {
                "pubchem_sid": 49895113,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1989-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 49895113,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1986-08-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.",
                "marketing_approval_date": "2000-12-21",
                "exclusivity_end_date": "2007-12-21",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical dystonia.",
                    "umls": "C0152116",
                    "parsed_text": "Cervical Dystonia"
                }
            },
            {
                "pubchem_sid": 49895113,
                "generic_name": "botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1991-12-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.",
                "marketing_approval_date": "2019-06-20",
                "exclusivity_end_date": "2026-06-20",
                "exclusivity_protected_indication": "For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Muscle contracture"
                    ]
                }
            },
            {
                "pubchem_sid": 49895113,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1998-08-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            },
            {
                "pubchem_sid": 49895113,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-29",
                "exclusivity_end_date": "1996-12-29",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            }
        ]
    },
    {
        "_id": "46505347",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46505347,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1991-12-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 46505347,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-30",
                "exclusivity_end_date": "1996-12-30",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            },
            {
                "pubchem_sid": 46505347,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Dysport",
                "designated_date": "1999-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lower limb spasticity in pediatric patients 2 years of age and older",
                "marketing_approval_date": "2016-07-29",
                "exclusivity_end_date": "2023-07-29",
                "exclusivity_protected_indication": "Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Contractures"
                    ]
                }
            },
            {
                "pubchem_sid": 46505347,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1989-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 46505347,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1986-08-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.",
                "marketing_approval_date": "2000-12-21",
                "exclusivity_end_date": "2007-12-21",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical dystonia.",
                    "umls": "C0152116",
                    "parsed_text": "Cervical Dystonia"
                }
            },
            {
                "pubchem_sid": 46505347,
                "generic_name": "botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1991-12-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.",
                "marketing_approval_date": "2019-06-20",
                "exclusivity_end_date": "2026-06-20",
                "exclusivity_protected_indication": "For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Muscle contracture"
                    ]
                }
            },
            {
                "pubchem_sid": 46505347,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1998-08-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            },
            {
                "pubchem_sid": 46505347,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-29",
                "exclusivity_end_date": "1996-12-29",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            }
        ]
    },
    {
        "_id": "10147",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 10147,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1991-12-05",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 10147,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-30",
                "exclusivity_end_date": "1996-12-30",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            },
            {
                "pubchem_sid": 10147,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Dysport",
                "designated_date": "1999-10-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of lower limb spasticity in pediatric patients 2 years of age and older",
                "marketing_approval_date": "2016-07-29",
                "exclusivity_end_date": "2023-07-29",
                "exclusivity_protected_indication": "Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older",
                "sponsor": "Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Contractures"
                    ]
                }
            },
            {
                "pubchem_sid": 10147,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1989-03-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States",
                "orphan_designation": {
                    "original_text": "Treatment of essential blepharospasm.",
                    "umls": "C2930898",
                    "parsed_text": "Essential blepharospasm"
                }
            },
            {
                "pubchem_sid": 10147,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1986-08-20",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.",
                "marketing_approval_date": "2000-12-21",
                "exclusivity_end_date": "2007-12-21",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of cervical dystonia.",
                    "umls": "C0152116",
                    "parsed_text": "Cervical Dystonia"
                }
            },
            {
                "pubchem_sid": 10147,
                "generic_name": "botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1991-12-06",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.",
                "marketing_approval_date": "2019-06-20",
                "exclusivity_end_date": "2026-06-20",
                "exclusivity_protected_indication": "For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States",
                "orphan_designation": {
                    "original_text": "Treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
                    "umls": [
                        "C0007789",
                        "C0009917"
                    ],
                    "parsed_text": [
                        "Cerebral Palsy",
                        "Muscle contracture"
                    ]
                }
            },
            {
                "pubchem_sid": 10147,
                "generic_name": "Botulinum toxin type A",
                "designated_date": "1998-08-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            },
            {
                "pubchem_sid": 10147,
                "generic_name": "Botulinum toxin type A",
                "trade_name": "Botox",
                "designated_date": "1984-03-22",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)",
                "marketing_approval_date": "1989-12-29",
                "exclusivity_end_date": "1996-12-29",
                "sponsor": "Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States",
                "orphan_designation": {
                    "original_text": "Treatment of strabismus and blepharospasms",
                    "umls": [
                        "C0005747",
                        "C0038379"
                    ],
                    "parsed_text": [
                        "Blepharospasms",
                        "Strabismus"
                    ]
                }
            }
        ]
    },
    {
        "_id": "312525292",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 312525292,
                "generic_name": "Botulinum toxin type F",
                "designated_date": "1991-10-24",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Ipsen Limited|27 Maple Street|Milford|Massachusetts|1757|United States",
                "orphan_designation": {
                    "original_text": "Treatment of spasmodic torticollis (cervical dystonia).",
                    "umls": "C0152116",
                    "parsed_text": "Spasmodic torticollis"
                }
            }
        ]
    },
    {
        "_id": "404720159",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404720159,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "381123584",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381123584,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "347910092",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910092,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "178101597",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178101597,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "160745599",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160745599,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "160745588",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160745588,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "160745577",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160745577,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "56311848",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 56311848,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "7978945",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 7978945,
                "generic_name": "Ciliary neurotrophic factor",
                "designated_date": "1992-01-30",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotrophic lateral sclerosis.",
                    "umls": "C0002736",
                    "parsed_text": "Amyotrophic Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "404772201",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772201,
                "generic_name": "mecasermin rinfabate",
                "trade_name": "Iplex",
                "designated_date": "2002-05-17",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone",
                "marketing_approval_date": "2005-12-12",
                "exclusivity_end_date": "2012-12-12",
                "sponsor": "Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of growth hormone insensitivity syndrome (GHIS)",
                    "umls": "C4318479",
                    "parsed_text": "Growth Hormone Insensitivity Syndrome"
                }
            },
            {
                "pubchem_sid": 404772201,
                "generic_name": "mecasermin rinfabate",
                "designated_date": "2012-09-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Premacure AB, a member of Shire Group of Companies|Dag Hammarskjolds vag 10B|Uppsala Science Park|Uppsala|Sweden",
                "orphan_designation": {
                    "original_text": "Prevention of retinopathy of prematurity in premature infants born at risk for the disease",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            },
            {
                "pubchem_sid": 404772201,
                "generic_name": "rhIGF-I/rhIGFBP-3",
                "designated_date": "2003-12-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)",
                    "umls": [
                        "C0265344",
                        "C0271695",
                        "C4313258"
                    ],
                    "parsed_text": [
                        "Leprechaunism",
                        "Rabson-Mendenhall Syndrome",
                        "Extreme insulin resistance"
                    ]
                }
            },
            {
                "pubchem_sid": 404772201,
                "generic_name": "mecasermin rinfabate",
                "designated_date": "2012-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PCUT BioPartners, Inc.|2196 Glenkirk Drive|San Jose|California|95124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotropic lateral sclerosis",
                    "umls": "C0154682",
                    "parsed_text": "Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "135325697",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135325697,
                "generic_name": "mecasermin rinfabate",
                "trade_name": "Iplex",
                "designated_date": "2002-05-17",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone",
                "marketing_approval_date": "2005-12-12",
                "exclusivity_end_date": "2012-12-12",
                "sponsor": "Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of growth hormone insensitivity syndrome (GHIS)",
                    "umls": "C4318479",
                    "parsed_text": "Growth Hormone Insensitivity Syndrome"
                }
            },
            {
                "pubchem_sid": 135325697,
                "generic_name": "mecasermin rinfabate",
                "designated_date": "2012-09-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Premacure AB, a member of Shire Group of Companies|Dag Hammarskjolds vag 10B|Uppsala Science Park|Uppsala|Sweden",
                "orphan_designation": {
                    "original_text": "Prevention of retinopathy of prematurity in premature infants born at risk for the disease",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            },
            {
                "pubchem_sid": 135325697,
                "generic_name": "rhIGF-I/rhIGFBP-3",
                "designated_date": "2003-12-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)",
                    "umls": [
                        "C0265344",
                        "C0271695",
                        "C4313258"
                    ],
                    "parsed_text": [
                        "Leprechaunism",
                        "Rabson-Mendenhall Syndrome",
                        "Extreme insulin resistance"
                    ]
                }
            },
            {
                "pubchem_sid": 135325697,
                "generic_name": "mecasermin rinfabate",
                "designated_date": "2012-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PCUT BioPartners, Inc.|2196 Glenkirk Drive|San Jose|California|95124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotropic lateral sclerosis",
                    "umls": "C0154682",
                    "parsed_text": "Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "103771459",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771459,
                "generic_name": "mecasermin rinfabate",
                "trade_name": "Iplex",
                "designated_date": "2002-05-17",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone",
                "marketing_approval_date": "2005-12-12",
                "exclusivity_end_date": "2012-12-12",
                "sponsor": "Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of growth hormone insensitivity syndrome (GHIS)",
                    "umls": "C4318479",
                    "parsed_text": "Growth Hormone Insensitivity Syndrome"
                }
            },
            {
                "pubchem_sid": 103771459,
                "generic_name": "mecasermin rinfabate",
                "designated_date": "2012-09-20",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Premacure AB, a member of Shire Group of Companies|Dag Hammarskjolds vag 10B|Uppsala Science Park|Uppsala|Sweden",
                "orphan_designation": {
                    "original_text": "Prevention of retinopathy of prematurity in premature infants born at risk for the disease",
                    "umls": "C0035344",
                    "parsed_text": "Retinopathy of Prematurity"
                }
            },
            {
                "pubchem_sid": 103771459,
                "generic_name": "rhIGF-I/rhIGFBP-3",
                "designated_date": "2003-12-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States",
                "orphan_designation": {
                    "original_text": "Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)",
                    "umls": [
                        "C0265344",
                        "C0271695",
                        "C4313258"
                    ],
                    "parsed_text": [
                        "Leprechaunism",
                        "Rabson-Mendenhall Syndrome",
                        "Extreme insulin resistance"
                    ]
                }
            },
            {
                "pubchem_sid": 103771459,
                "generic_name": "mecasermin rinfabate",
                "designated_date": "2012-07-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "PCUT BioPartners, Inc.|2196 Glenkirk Drive|San Jose|California|95124|United States",
                "orphan_designation": {
                    "original_text": "Treatment of amyotropic lateral sclerosis",
                    "umls": "C0154682",
                    "parsed_text": "Lateral Sclerosis"
                }
            }
        ]
    },
    {
        "_id": "440790866",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790866,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 440790866,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 440790866,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 440790866,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "387060162",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387060162,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 387060162,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 387060162,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 387060162,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "347910355",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910355,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 347910355,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 347910355,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 347910355,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "329976991",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 329976991,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 329976991,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 329976991,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 329976991,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "178103384",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103384,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 178103384,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 178103384,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 178103384,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "135302238",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135302238,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 135302238,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 135302238,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 135302238,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "103771534",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771534,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 103771534,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 103771534,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 103771534,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "426391582",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 426391582,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 426391582,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 426391582,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 426391582,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "349995626",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349995626,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "marketing_approval_date": "2014-04-17",
                "exclusivity_end_date": "2021-04-17",
                "exclusivity_protected_indication": "Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 349995626,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).",
                "marketing_approval_date": "2016-08-30",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 349995626,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine",
                "marketing_approval_date": "2009-10-26",
                "exclusivity_end_date": "2016-10-26",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 349995626,
                "generic_name": "ofatumumab",
                "trade_name": "ARZERRA",
                "designated_date": "2009-03-10",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "marketing_approval_date": "2016-01-19",
                "exclusivity_end_date": "2023-01-19",
                "exclusivity_protected_indication": "For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.",
                "sponsor": "Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            }
        ]
    },
    {
        "_id": "433770930",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 433770930,
                "generic_name": "Penpulimab",
                "designated_date": "2021-02-23",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Akeso Biopharma, Inc.|6 Shennong Road, Torch Development Zone|Zhongshan|Guangdong|528437|China",
                "orphan_designation": {
                    "original_text": "Treatment of nasopharyngeal carcinoma",
                    "umls": "C2931822",
                    "parsed_text": "Nasopharyngeal carcinoma"
                }
            }
        ]
    },
    {
        "_id": "404772511",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772511,
                "generic_name": "pexastimogene devacirepvec",
                "designated_date": "2013-05-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SillaJen Biotherapeutics, Inc.|450 Sansome Street|Suite 200|San Francisco|California|94111|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "pubchem_sid": 404772511,
                "generic_name": "Pexastimogene Devacirepvec",
                "designated_date": "2020-09-14",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SillaJen, Inc.|6F, 111, Hyoyeol-ro|Suite 200|Buk-gu|Busan|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIB-IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "174489633",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 174489633,
                "generic_name": "pexastimogene devacirepvec",
                "designated_date": "2013-05-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SillaJen Biotherapeutics, Inc.|450 Sansome Street|Suite 200|San Francisco|California|94111|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "pubchem_sid": 174489633,
                "generic_name": "Pexastimogene Devacirepvec",
                "designated_date": "2020-09-14",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SillaJen, Inc.|6F, 111, Hyoyeol-ro|Suite 200|Buk-gu|Busan|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIB-IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "135314152",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135314152,
                "generic_name": "pexastimogene devacirepvec",
                "designated_date": "2013-05-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SillaJen Biotherapeutics, Inc.|450 Sansome Street|Suite 200|San Francisco|California|94111|United States",
                "orphan_designation": {
                    "original_text": "Treatment of hepatocellular carcinoma",
                    "umls": "C2239176",
                    "parsed_text": "HEPATOCELLULAR CARCINOMA"
                }
            },
            {
                "pubchem_sid": 135314152,
                "generic_name": "Pexastimogene Devacirepvec",
                "designated_date": "2020-09-14",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "SillaJen, Inc.|6F, 111, Hyoyeol-ro|Suite 200|Buk-gu|Busan|South Korea",
                "orphan_designation": {
                    "original_text": "Treatment of stage IIB-IV melanoma",
                    "umls": "C0025202",
                    "parsed_text": "melanoma"
                }
            }
        ]
    },
    {
        "_id": "347910027",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910027,
                "generic_name": "rozrolimupab",
                "designated_date": "2010-09-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Symphogen A/S|Pederstrupvej 93|Ballerup|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of primary immune thrombocytopenia.",
                    "umls": "C0242584",
                    "parsed_text": "Immune thrombocytopenia"
                }
            }
        ]
    },
    {
        "_id": "160676887",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160676887,
                "generic_name": "rozrolimupab",
                "designated_date": "2010-09-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Symphogen A/S|Pederstrupvej 93|Ballerup|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of primary immune thrombocytopenia.",
                    "umls": "C0242584",
                    "parsed_text": "Immune thrombocytopenia"
                }
            }
        ]
    },
    {
        "_id": "135318292",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135318292,
                "generic_name": "rozrolimupab",
                "designated_date": "2010-09-13",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Symphogen A/S|Pederstrupvej 93|Ballerup|Denmark",
                "orphan_designation": {
                    "original_text": "Treatment of primary immune thrombocytopenia.",
                    "umls": "C0242584",
                    "parsed_text": "Immune thrombocytopenia"
                }
            }
        ]
    },
    {
        "_id": "374364310",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 374364310,
                "generic_name": "tabelecleucel",
                "designated_date": "2016-02-04",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ATARA Biotherapeutics, Inc.|4360 Park Terrace Drive|Suite 100|Westlake Village|California|91361|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders",
                    "umls": [
                        "C0014644",
                        "C0024314"
                    ],
                    "parsed_text": [
                        "Epstein-Barr virus",
                        "Lymphoproliferative Disorders"
                    ]
                }
            }
        ]
    },
    {
        "_id": "347910350",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910350,
                "generic_name": "C1 esterase inhibitor (human)",
                "trade_name": "Cinryze(r)",
                "designated_date": "2004-07-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).",
                "marketing_approval_date": "2018-06-20",
                "exclusivity_end_date": "2025-06-20",
                "exclusivity_protected_indication": "CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).",
                "sponsor": "ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "pubchem_sid": 347910350,
                "generic_name": "C1 esterase inhibitor (human)",
                "trade_name": "Cinryze(r)",
                "designated_date": "2004-07-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)",
                "marketing_approval_date": "2008-10-10",
                "exclusivity_end_date": "2015-10-10",
                "sponsor": "ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "pubchem_sid": 347910350,
                "generic_name": "C1 esterase inhibitor (human)",
                "designated_date": "1996-08-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alpha Therapeutic Corporation|5555 Valley Boulevard|Los Angeles|California|90032|United States",
                "orphan_designation": {
                    "original_text": "Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.",
                    "umls": "C0002994",
                    "parsed_text": "Angioedema"
                }
            }
        ]
    },
    {
        "_id": "333495402",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 333495402,
                "generic_name": "C1 esterase inhibitor (human)",
                "trade_name": "Cinryze(r)",
                "designated_date": "2004-07-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).",
                "marketing_approval_date": "2018-06-20",
                "exclusivity_end_date": "2025-06-20",
                "exclusivity_protected_indication": "CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).",
                "sponsor": "ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "pubchem_sid": 333495402,
                "generic_name": "C1 esterase inhibitor (human)",
                "trade_name": "Cinryze(r)",
                "designated_date": "2004-07-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)",
                "marketing_approval_date": "2008-10-10",
                "exclusivity_end_date": "2015-10-10",
                "sponsor": "ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States",
                "orphan_designation": {
                    "original_text": "Treatment of angioedema",
                    "umls": "C0002994",
                    "parsed_text": "Angioedema"
                }
            },
            {
                "pubchem_sid": 333495402,
                "generic_name": "C1 esterase inhibitor (human)",
                "designated_date": "1996-08-21",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Alpha Therapeutic Corporation|5555 Valley Boulevard|Los Angeles|California|90032|United States",
                "orphan_designation": {
                    "original_text": "Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.",
                    "umls": "C0002994",
                    "parsed_text": "Angioedema"
                }
            }
        ]
    },
    {
        "_id": "441072534",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 441072534,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 441072534,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "440790407",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 440790407,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 440790407,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "387061216",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387061216,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 387061216,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "384060698",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384060698,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 384060698,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "384060466",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384060466,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 384060466,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "329976962",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 329976962,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 329976962,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "178103395",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103395,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 178103395,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "135343504",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135343504,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 135343504,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "103771203",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771203,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 103771203,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "50059111",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50059111,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 50059111,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "46506732",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46506732,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 46506732,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "7979194",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 7979194,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 7979194,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "10099",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 10099,
                "generic_name": "Etanercept",
                "designated_date": "1999-04-06",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Immunex Corporation|51 University Street|Seattle|Washington|98101|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Wegener's granulomatosis.",
                    "umls": "C3495801",
                    "parsed_text": "Wegener's Granulomatosis"
                }
            },
            {
                "pubchem_sid": 10099,
                "generic_name": "etanercept",
                "trade_name": "Enbrel",
                "designated_date": "1998-10-27",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older",
                "marketing_approval_date": "1999-05-27",
                "exclusivity_end_date": "2006-05-27",
                "sponsor": "Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States",
                "orphan_designation": {
                    "original_text": "Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.",
                    "umls": "C3495559",
                    "parsed_text": "Juvenile rheumatoid arthritis"
                }
            }
        ]
    },
    {
        "_id": "349427652",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349427652,
                "generic_name": "etaracizumab",
                "designated_date": "2004-04-14",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",
                    "umls": "C0278883",
                    "parsed_text": "stage iv melanoma"
                }
            }
        ]
    },
    {
        "_id": "347911300",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911300,
                "generic_name": "etaracizumab",
                "designated_date": "2004-04-14",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",
                    "umls": "C0278883",
                    "parsed_text": "stage iv melanoma"
                }
            }
        ]
    },
    {
        "_id": "178103209",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103209,
                "generic_name": "etaracizumab",
                "designated_date": "2004-04-14",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",
                    "umls": "C0278883",
                    "parsed_text": "stage iv melanoma"
                }
            }
        ]
    },
    {
        "_id": "160666626",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160666626,
                "generic_name": "etaracizumab",
                "designated_date": "2004-04-14",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",
                    "umls": "C0278883",
                    "parsed_text": "stage iv melanoma"
                }
            }
        ]
    },
    {
        "_id": "135323725",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135323725,
                "generic_name": "etaracizumab",
                "designated_date": "2004-04-14",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States",
                "orphan_designation": {
                    "original_text": "For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",
                    "umls": "C0278883",
                    "parsed_text": "stage iv melanoma"
                }
            }
        ]
    },
    {
        "_id": "347911285",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911285,
                "generic_name": "gevokizumab",
                "designated_date": "2010-07-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 347911285,
                "generic_name": "gevokizumab",
                "designated_date": "2012-08-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0042164",
                        "C0339317"
                    ],
                    "parsed_text": [
                        "Uveitis",
                        "Non-infectious anterior uveitis"
                    ]
                }
            },
            {
                "pubchem_sid": 347911285,
                "generic_name": "gevokizumab",
                "designated_date": "2014-02-21",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pyoderma gangrenosum",
                    "umls": "C0085652",
                    "parsed_text": "Pyoderma Gangrenosum"
                }
            }
        ]
    },
    {
        "_id": "178103966",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103966,
                "generic_name": "gevokizumab",
                "designated_date": "2010-07-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 178103966,
                "generic_name": "gevokizumab",
                "designated_date": "2012-08-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0042164",
                        "C0339317"
                    ],
                    "parsed_text": [
                        "Uveitis",
                        "Non-infectious anterior uveitis"
                    ]
                }
            },
            {
                "pubchem_sid": 178103966,
                "generic_name": "gevokizumab",
                "designated_date": "2014-02-21",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pyoderma gangrenosum",
                    "umls": "C0085652",
                    "parsed_text": "Pyoderma Gangrenosum"
                }
            }
        ]
    },
    {
        "_id": "160704155",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160704155,
                "generic_name": "gevokizumab",
                "designated_date": "2010-07-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 160704155,
                "generic_name": "gevokizumab",
                "designated_date": "2012-08-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0042164",
                        "C0339317"
                    ],
                    "parsed_text": [
                        "Uveitis",
                        "Non-infectious anterior uveitis"
                    ]
                }
            },
            {
                "pubchem_sid": 160704155,
                "generic_name": "gevokizumab",
                "designated_date": "2014-02-21",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pyoderma gangrenosum",
                    "umls": "C0085652",
                    "parsed_text": "Pyoderma Gangrenosum"
                }
            }
        ]
    },
    {
        "_id": "135322326",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135322326,
                "generic_name": "gevokizumab",
                "designated_date": "2010-07-27",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Behcet's disease",
                    "umls": "C0004943",
                    "parsed_text": "Behcet Syndrome"
                }
            },
            {
                "pubchem_sid": 135322326,
                "generic_name": "gevokizumab",
                "designated_date": "2012-08-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",
                    "umls": [
                        "C0042164",
                        "C0339317"
                    ],
                    "parsed_text": [
                        "Uveitis",
                        "Non-infectious anterior uveitis"
                    ]
                }
            },
            {
                "pubchem_sid": 135322326,
                "generic_name": "gevokizumab",
                "designated_date": "2014-02-21",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pyoderma gangrenosum",
                    "umls": "C0085652",
                    "parsed_text": "Pyoderma Gangrenosum"
                }
            }
        ]
    },
    {
        "_id": "404772323",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 404772323,
                "generic_name": "lintuzumab",
                "designated_date": "2007-01-30",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "pubchem_sid": 404772323,
                "generic_name": "lintuzumab",
                "designated_date": "2007-03-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "pubchem_sid": 404772323,
                "generic_name": "lintuzumab",
                "designated_date": "2002-09-09",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "249565664",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 249565664,
                "generic_name": "lintuzumab",
                "designated_date": "2007-01-30",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "pubchem_sid": 249565664,
                "generic_name": "lintuzumab",
                "designated_date": "2007-03-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "pubchem_sid": 249565664,
                "generic_name": "lintuzumab",
                "designated_date": "2002-09-09",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "160671685",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 160671685,
                "generic_name": "lintuzumab",
                "designated_date": "2007-01-30",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "pubchem_sid": 160671685,
                "generic_name": "lintuzumab",
                "designated_date": "2007-03-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "pubchem_sid": 160671685,
                "generic_name": "lintuzumab",
                "designated_date": "2002-09-09",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "135336964",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135336964,
                "generic_name": "lintuzumab",
                "designated_date": "2007-01-30",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myeloid leukemia.",
                    "umls": "C0023467",
                    "parsed_text": "Acute myeloid leukemia"
                }
            },
            {
                "pubchem_sid": 135336964,
                "generic_name": "lintuzumab",
                "designated_date": "2007-03-20",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States",
                "orphan_designation": {
                    "original_text": "Treatment of myelodysplastic syndrome",
                    "umls": "C3463824",
                    "parsed_text": "MYELODYSPLASTIC SYNDROME"
                }
            },
            {
                "pubchem_sid": 135336964,
                "generic_name": "lintuzumab",
                "designated_date": "2002-09-09",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States",
                "orphan_designation": {
                    "original_text": "Treatment of acute myelogenous leukemia",
                    "umls": "C0023467",
                    "parsed_text": "Acute myelogenous leukemia"
                }
            }
        ]
    },
    {
        "_id": "347910234",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347910234,
                "generic_name": "Recombinant human relaxin",
                "designated_date": "1995-11-03",
                "designation_status": "Designated/Withdrawn",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Connetics Corporation|3400 West Bayshore Road|Palo Alto|California|94303|United States",
                "orphan_designation": {
                    "original_text": "Treatment of progressive systemic sclerosis.",
                    "umls": "C1258104",
                    "parsed_text": "Progressive systemic sclerosis"
                }
            }
        ]
    },
    {
        "_id": "441072531",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 441072531,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "387061212",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 387061212,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "385327556",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 385327556,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "384647099",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 384647099,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "365372203",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 365372203,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "354355036",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 354355036,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "348838049",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 348838049,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "329976960",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 329976960,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "319478935",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 319478935,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "319435463",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 319435463,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "178103386",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 178103386,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "135341754",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 135341754,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "103771410",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 103771410,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "57288666",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 57288666,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "56314417",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 56314417,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "50070184",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 50070184,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "46505820",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2004-01-29",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide",
                "marketing_approval_date": "2010-02-18",
                "exclusivity_end_date": "2017-02-18",
                "sponsor": "Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of chronic lymphocytic leukemia",
                    "umls": "C0023434",
                    "parsed_text": "Chronic Lymphocytic Leukemia"
                }
            },
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )",
                "marketing_approval_date": "2011-04-19",
                "exclusivity_end_date": "2018-04-19",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "2006-02-14",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)",
                "marketing_approval_date": "2019-09-27",
                "exclusivity_end_date": "2026-09-27",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",
                    "umls": [
                        "C0008728",
                        "C2347126",
                        "C2717865",
                        "C3495801"
                    ],
                    "parsed_text": [
                        "Churg-Strauss Syndrome",
                        "Microscopic Polyangiitis",
                        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
                        "Wegener's Granulomatosis"
                    ]
                }
            },
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "designated_date": "2020-11-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel",
                "orphan_designation": {
                    "original_text": "Treatment of autoimmune hemolytic anemia",
                    "umls": "C0002880",
                    "parsed_text": "Autoimmune hemolytic anemia"
                }
            },
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "trade_name": "Rituxan",
                "designated_date": "1994-06-13",
                "designation_status": "Designated/Approved",
                "marketing_approval_date": "1997-11-26",
                "exclusivity_end_date": "2004-11-26",
                "sponsor": "Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of non-Hodgkin's B-cell lymphoma",
                    "umls": "C0079731",
                    "parsed_text": "non-Hodgkin's B-cell lymphoma"
                }
            },
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "trade_name": "Rituxan(r); MabThera(r)",
                "designated_date": "2015-02-23",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "marketing_approval_date": "2018-06-07",
                "exclusivity_end_date": "2025-06-07",
                "exclusivity_protected_indication": "RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of pemphigus vulgaris.",
                    "umls": "C0030809",
                    "parsed_text": "Pemphigus Vulgaris"
                }
            },
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "designated_date": "2016-11-09",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States",
                "orphan_designation": {
                    "original_text": "Treatment of Rasmussen's encephalitis",
                    "umls": "C0393484",
                    "parsed_text": "Rasmussen Encephalitis"
                }
            },
            {
                "pubchem_sid": 46505820,
                "generic_name": "rituximab",
                "designated_date": "2002-03-12",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States",
                "orphan_designation": {
                    "original_text": "Treatment of immune thrombocytopenic purpura",
                    "umls": "C0398650",
                    "parsed_text": "Immune thrombocytopenic purpura"
                }
            }
        ]
    },
    {
        "_id": "381127826",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 381127826,
                "generic_name": "vestronidase alfa-vjbk",
                "trade_name": "Mepsevii",
                "designated_date": "2012-02-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).",
                "marketing_approval_date": "2017-11-15",
                "exclusivity_end_date": "2024-11-15",
                "exclusivity_protected_indication": "Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).",
                "sponsor": "Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",
                    "umls": "C0085132",
                    "parsed_text": "Mucopolysaccharidosis VII"
                }
            }
        ]
    },
    {
        "_id": "374364116",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 374364116,
                "generic_name": "vestronidase alfa-vjbk",
                "trade_name": "Mepsevii",
                "designated_date": "2012-02-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).",
                "marketing_approval_date": "2017-11-15",
                "exclusivity_end_date": "2024-11-15",
                "exclusivity_protected_indication": "Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).",
                "sponsor": "Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",
                    "umls": "C0085132",
                    "parsed_text": "Mucopolysaccharidosis VII"
                }
            }
        ]
    },
    {
        "_id": "347911326",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347911326,
                "generic_name": "vestronidase alfa-vjbk",
                "trade_name": "Mepsevii",
                "designated_date": "2012-02-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).",
                "marketing_approval_date": "2017-11-15",
                "exclusivity_end_date": "2024-11-15",
                "exclusivity_protected_indication": "Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).",
                "sponsor": "Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",
                    "umls": "C0085132",
                    "parsed_text": "Mucopolysaccharidosis VII"
                }
            }
        ]
    },
    {
        "_id": "342581841",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 342581841,
                "generic_name": "vestronidase alfa-vjbk",
                "trade_name": "Mepsevii",
                "designated_date": "2012-02-16",
                "designation_status": "Designated/Approved",
                "approved_labeled_indication": "Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).",
                "marketing_approval_date": "2017-11-15",
                "exclusivity_end_date": "2024-11-15",
                "exclusivity_protected_indication": "Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).",
                "sponsor": "Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States",
                "orphan_designation": {
                    "original_text": "Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",
                    "umls": "C0085132",
                    "parsed_text": "Mucopolysaccharidosis VII"
                }
            }
        ]
    },
    {
        "_id": "349272539",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349272539,
                "generic_name": "ferumoxytol",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",
                    "umls": [
                        "C0006826",
                        "C0280099"
                    ],
                    "parsed_text": [
                        "MALIGNANCIES",
                        "Solid Tumor"
                    ]
                }
            },
            {
                "pubchem_sid": 349272539,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-04-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in MR imaging for the mangement of brain tumors",
                    "umls": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            },
            {
                "pubchem_sid": 349272539,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-10-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging in brain metastases",
                    "umls": "C0220650",
                    "parsed_text": "brain metastases"
                }
            }
        ]
    },
    {
        "_id": "347827764",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 347827764,
                "generic_name": "ferumoxytol",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",
                    "umls": [
                        "C0006826",
                        "C0280099"
                    ],
                    "parsed_text": [
                        "MALIGNANCIES",
                        "Solid Tumor"
                    ]
                }
            },
            {
                "pubchem_sid": 347827764,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-04-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in MR imaging for the mangement of brain tumors",
                    "umls": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            },
            {
                "pubchem_sid": 347827764,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-10-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging in brain metastases",
                    "umls": "C0220650",
                    "parsed_text": "brain metastases"
                }
            }
        ]
    },
    {
        "_id": "135263533",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 135263533,
                "generic_name": "ferumoxytol",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",
                    "umls": [
                        "C0006826",
                        "C0280099"
                    ],
                    "parsed_text": [
                        "MALIGNANCIES",
                        "Solid Tumor"
                    ]
                }
            },
            {
                "pubchem_sid": 135263533,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-04-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in MR imaging for the mangement of brain tumors",
                    "umls": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            },
            {
                "pubchem_sid": 135263533,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-10-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging in brain metastases",
                    "umls": "C0220650",
                    "parsed_text": "brain metastases"
                }
            }
        ]
    },
    {
        "_id": "104234375",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 104234375,
                "generic_name": "ferumoxytol",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",
                    "umls": [
                        "C0006826",
                        "C0280099"
                    ],
                    "parsed_text": [
                        "MALIGNANCIES",
                        "Solid Tumor"
                    ]
                }
            },
            {
                "pubchem_sid": 104234375,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-04-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in MR imaging for the mangement of brain tumors",
                    "umls": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            },
            {
                "pubchem_sid": 104234375,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-10-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging in brain metastases",
                    "umls": "C0220650",
                    "parsed_text": "brain metastases"
                }
            }
        ]
    },
    {
        "_id": "386330730",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 386330730,
                "generic_name": "ferumoxytol",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",
                    "umls": [
                        "C0006826",
                        "C0280099"
                    ],
                    "parsed_text": [
                        "MALIGNANCIES",
                        "Solid Tumor"
                    ]
                }
            },
            {
                "pubchem_sid": 386330730,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-04-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in MR imaging for the mangement of brain tumors",
                    "umls": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            },
            {
                "pubchem_sid": 386330730,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-10-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging in brain metastases",
                    "umls": "C0220650",
                    "parsed_text": "brain metastases"
                }
            }
        ]
    },
    {
        "_id": "349995325",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349995325,
                "generic_name": "ferumoxytol",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",
                    "umls": [
                        "C0006826",
                        "C0280099"
                    ],
                    "parsed_text": [
                        "MALIGNANCIES",
                        "Solid Tumor"
                    ]
                }
            },
            {
                "pubchem_sid": 349995325,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-04-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in MR imaging for the mangement of brain tumors",
                    "umls": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            },
            {
                "pubchem_sid": 349995325,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-10-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging in brain metastases",
                    "umls": "C0220650",
                    "parsed_text": "brain metastases"
                }
            }
        ]
    },
    {
        "_id": "349980335",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 349980335,
                "generic_name": "ferumoxytol",
                "designated_date": "2012-04-06",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",
                    "umls": [
                        "C0006826",
                        "C0280099"
                    ],
                    "parsed_text": [
                        "MALIGNANCIES",
                        "Solid Tumor"
                    ]
                }
            },
            {
                "pubchem_sid": 349980335,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-04-29",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in MR imaging for the mangement of brain tumors",
                    "umls": "C0006118",
                    "parsed_text": "Brain Tumors"
                }
            },
            {
                "pubchem_sid": 349980335,
                "generic_name": "ferumoxytol",
                "designated_date": "2011-10-07",
                "designation_status": "Designated",
                "approval_status": "Not FDA Approved for Orphan Indication",
                "sponsor": "Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States",
                "orphan_designation": {
                    "original_text": "For use in magnetic resonance imaging in brain metastases",
                    "umls": "C0220650",
                    "parsed_text": "brain metastases"
                }
            }
        ]
    },
    {
        "_id": "341169549",
        "fda_orphan_drug": [
            {
                "pubchem_sid": 341169549,